10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2014

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission file number: 000-53595

SUNWIN STEVIA INTERNATIONAL, INC.

(Exact name of registrant as specified in charter)

NEVADA	56-2416925
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6 SHENGWANG AVE., QUFU, SHANDONG, CHINA	273100
(Address of principal executive offices)	(Zip Code)

(86) 537-4424999

(Registrant's telephone number, including area code)

NOT APPLICABLE

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No [  ]

Indicate by check mark whether the registrant has been submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ ] No [x]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  [  ]	Accelerated filer                   [  ]
Non-accelerated filer    [  ]	Smaller reporting company  [x]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ] No [x].

Indicate the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: As of March 16, 2014 there were 173,882,803 shares of the registrant's common stock issued and outstanding.

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

FORM 10-Q

 QUARTERLY PERIOD ENDED JANUARY 31, 2014

INDEX

	Page
PART I-FINANCIAL INFORMATION
Item 1.    Financial Statements	1
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.    Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.    Controls and Procedures	26
PART II-OTHER INFORMATION
Item 1.     Legal Proceedings	27
Item 1A.  Risk Factors	27
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.     Defaults Upon Senior Securities	27
Item 4.     Mine Safety Disclosures	27
Item 5.     Other Information	27
Item 6.     Exhibits	27

i

Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results

This report contains forward-looking statements. The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. A list of factors that could cause our actual results of operations and financial condition to differ materially is set forth below, and these factors are discussed in greater detail under Item 1A – "Risk Factors" in our Annual Report on Form 10-K for the year ended April 30, 2013 as filed with the Securities and Exchange Commission:

- Our revenues have declined in the past two fiscal years and there are no assurances they will return to historic levels in future periods;

- Growing dependence on related party revenues;

- Dependence upon continued market acceptance of our stevioside products, maintaining Generally Recognized as Safe status in the United States and obtaining approval in other countries in the world that currently do not permit use of steviosides in food products;

- Competition and low barriers to entry to the market in which we sell our products;

- Our dependence on the services of our president;

- Our inability to control the cost of our raw materials;

- The limitation on our ability to receive and use our cash flows effectively as a result of restrictions on currency exchange in the PRC;

- Our operations are subject to government regulation. If we fail to comply with the applicable regulations, our ability to operate in future periods could be in jeopardy;

- The absence of various corporate governance measures which may reduce stockholders’ protections against interested director transactions, conflicts of interest and other matters;

- The effect of changes resulting from the political and economic policies of the Chinese government on our assets and operations located in the PRC;

- The impact of economic reform policies in the PRC;

- The influence of the Chinese government over the manner in which our Chinese subsidiaries must conduct our business activities;

- The impact of any natural disasters and health epidemics in China;

- Regulations relating to offshore investment activities by Chinese residents may increase the administrative burden we face and create regulatory uncertainties that may limit or adversely affect our ability to complete a business combination with PRC companies;

- The lack of various legal protections in certain agreements to which we are a party and which are material to our operations which are customarily contained in similar contracts prepared in the United States;

- Our ability to enforce our rights due to policies regarding the regulation of foreign investments in China;

- Difficulties stockholders may face who seek to enforce any judgment obtained in the United States against us, which may limit the remedies otherwise available to our stockholders;

- Our ability to comply with the United States Foreign Corrupt Practices Act which could subject us to penalties and other adverse consequences;

- Provisions of our articles of incorporation and bylaws may delay or prevent a take-over which may not be in the best interests of our stockholders;

- Our dependence on our corporate management services in the preparation of our financial statements and reports we file with the SEC.

- Adverse affects on the liquidity of our stock because it currently trades below $5.00 per share, is quoted on the OTC bulletin board, and is considered a “penny stock;” and

- The impact on our stock price due to future sales of restricted stock held by existing shareholders.

ii

We caution that the factors described herein and other factors could cause our actual results of operations and financial condition to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned to review our Annual Report on Form 10-K for the year ended April 30, 2013 and our subsequent filings with the Securities and Exchange Commission.  We undertake no obligation to publicly update any foward-looking statements except as may be required by Federal securities laws.

INDEX OF CERTAIN DEFINED TERMS USED IN THIS REPORT

We are on a fiscal year ending April 30, as such the year ended April 30, 2013 is referred to as “fiscal 2013” and the year ending April 30, 2014 is referred to as “fiscal 2014.”  Also, the three month period ending January 31, 2014 is our third quarter and is referred to as the “third quarter of fiscal 2014”. Likewise, the three month period ending January 31, 2013 is referred to as the “third quarter of fiscal 2013”.

When used in this report, the terms:
	-	“Sunwin”, “we”, “us” and the “Company” refers to Sunwin Stevia International, Inc., a Nevada corporation formerly known as Sunwin Neutraceuticals International, Inc., and our subsidiaries;
	-	“Sunwin Tech” refers to our wholly owned subsidiary Sunwin Tech Group, Inc., a Florida corporation;
	-	“Qufu Natural Green” refers to our wholly owned subsidiary Qufu Natural Green Engineering Co., Ltd., a Chinese limited liability company;
	-	“Sunwin Stevia International” refers to our wholly owned subsidiary Sunwin Stevia International Corp., a Florida corporation, which was converted to Sunwin USA, LLC a Delaware limited liability company in May 2009;
	-	“Sunwin USA” refers to Sunwin USA, LLC, a Delaware limited liability company, a 100% owned subsidiary;
	-	“Qufu Shengwang” refers to Qufu Shengwang Stevia Biology and Science Co., Ltd., a Chinese limited liability company. Qufu Natural Green owns a 100% interest in Qufu Shengwang; and
	-	“Qufu Shengren” refers to Qufu Shengren Pharmaceutical Co., Ltd., a Chinese limited liability company, and a wholly owned subsidiary of Qufu Natural Green.
We also use the following terms when referring to certain related and other parties:
	-	“Pharmaceutical Corporation” refers to Shandong Shengwang Pharmaceutical Co., Ltd., a Chinese limited liability company which is managed by Mr. Laiwang Zhang,  President, Chairman and a principal shareholder of our company;
	-	"Qufu Shengwang Import and Export" refers to Qufu Shengwang Import and Export Co., Ltd., a Chinese limited liability company, managed by Mr. Zhang;
	-	“Shandong Group” refers to Shandong Shengwang Group Co., Ltd., a Chinese limited liability company, which is managed by Mr. Zhang,  and
	-	“WILD Flavors” refers to WILD Flavors, Inc., a Delaware corporation.

The information which appears on our website at www.sunwininternational.com is not part of this report.

iii

PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

Insert Financials 

CONDENSED CONSOLIDATED BALANCE SHEETS
	January 31,			April 30,
	2014			2013
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	830,035		$	517,106
Accounts receivable, net of allowance for doubtful accounts of $1,134,102 and $1,000,291, respectively		1,397,527			1,614,152
Accounts receivable - related party		644,448			1,239,222
Notes receivable		-			41,851
Loans receivable		-			43,614
Inventories, net		4,829,146			4,927,971
Prepaid expenses and other current assets		1,300,365			1,189,416
Total Current Assets		9,001,521			9,573,332
Investment in real estate held for resale		1,981,879			1,947,042
Property and equipment, net		14,936,633			15,725,384
Intangible assets, net		1,165,209			1,409,090
Land use rights, net		2,287,635			2,289,544
Total Assets	$	29,372,877		$	30,944,392
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	3,310,019		$	3,626,117
Loan payable		-			804,829
Deferred grant income		764,614			-
Due to related party		220,883			174,404
Total Current Liabilities		4,295,516			4,605,350
Commitments
STOCKHOLDERS' EQUITY:
Preferred stock, $0.001 par value; 1,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.001 par value, 200,000,000 shares authorized; 173,882,803 and 173,882,803 shares issued and outstanding as of January 31, 2014 and April 30, 2013, respectively		173,883			173,883
Additional paid-in capital		33,479,529			33,479,529
Accumulated deficit		(14,539,152	)		(12,829,706	)
Accumulated other comprehensive income		5,963,101			5,515,336
Total Stockholders' Equity		25,077,361			26,339,042
Total Liabilities and Stockholders' Equity	$	29,372,877		$	30,944,392
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

- 1 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
	For the Three Months Ended January 31,						For the Nine Months Ended January 31,
	2014			2013			2014			2013
Revenues	$	2,394,691		$	1,798,944		$	6,201,563		$	6,091,339
Revenues - related party		833,657			171,547			2,567,648			1,576,463
Total revenues		3,228,348			1,970,491			8,769,211			7,667,802
Cost of revenues		2,549,994			1,572,761			7,344,223			6,212,586
Gross profit		678,354			397,730			1,424,988			1,455,216
Operating expenses:
Loss on disposition of property and equipment		-			209,194			-			209,194
Selling expenses		361,417			261,452			930,684			751,873
General and administrative expenses		818,861			737,802			2,621,703			3,551,722
Total operating expenses		1,180,278			1,208,448			3,552,387			4,512,789
Loss from operations		(501,924	)		(810,718	)		(2,127,399	)		(3,057,573	)
Other income (expenses):
Other income (expenses)		371,343			(20,204	)		486,858			(15,553	)
Interest (expenses) income		(35,481	)		637			(68,731	)		8,170
Total other income		335,862			(19,567	)		418,127			(7,383	)
Loss before income taxes		(166,062	)		(830,285	)		(1,709,272	)		(3,064,956	)
Income taxes expense		-			3,444			(174	)		-
Net loss	$	(166,062	)	$	(826,841	)	$	(1,709,446	)	$	(3,064,956	)
Comprehensive loss:
Net loss	$	(166,062	)	$	(826,841	)	$	(1,709,446	)	$	(3,064,956	)
Foreign currency translation adjustment		30,286			11,377			447,765			74,779
Total comprehensive loss	$	(135,776	)	$	(815,464	)	$	(1,261,681	)	$	(2,990,177	)
Net loss per common share:
Net loss per share - basic and diluted	$	(0.001	)	$	(0.005	)	$	(0.010	)	$	(0.018	)
Weighted average common shares outstanding - basic and diluted		173,882,803			173,374,671			173,882,803			165,946,391
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

- 2 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
	For the Nine Months Ended January 31,
	2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,709,446	)	$	(3,064,956	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation expense		1,346,728			1,240,136
Amortization of intangible assets		243,881			135,490
Amortization of land use right		43,090			42,022
Realized comprehensive loss		1,535			-
Loss on disposition of property and equipment		-			209,194
Stock issued for employee compensation		-			810,000
Stock issued for services		-			614,959
Inventory impairment change		-			(3,593	)
Allowance for doubtful accounts		115,101			(91,648	)
Changes in operating assets and liabilities:
Accounts receivable and notes receivable		170,984			982,660
Accounts receivable - related party		612,620			(175,178	)
Inventories		185,685			(968,145	)
Prepaid expenses and other current assets		(185,478	)		(937,729	)
Due from related party		-			(792,126	)
Tax receivable		-			(135,966	)
Accounts payable and accrued expenses		(391,893	)		(263,390	)
Deferred grant income		759,252			-
Taxes payable		110,144			(73,310	)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES		1,302,203			(2,471,580	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(273,794	)		(2,677,493	)
Increase in loan receivable		-			(1,718	)
Proceeds from loan receivable		43,614			1,921,358
NET CASH (USED IN) INVESTING ACTIVITIES		(230,180	)		(757,853	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of short-term loan		(813,484	)		-
Advance due to related party		-			351,873
Proceed from (repayment of) related party advances		43,052			(12,546	)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES		(770,432	)		339,327
EFFECT OF EXCHANGE RATE ON CASH		12,894			(495	)
NET INCREASE (DECREASE) IN CASH		312,929			(2,890,601	)
Cash at the beginning of year		517,106			2,958,895
Cash at the end of period	$	830,035		$	68,294
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes	$	174		$	35,092
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Intangible assets acquired from acquisition	$	-		$	1,625,874
Shares issued for acquisition	$	-		$	1,625,874
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

- 3 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

NOTE 1 - ORGANIZATION AND OPERATIONS

DESCRIPTION OF BUSINESS

Sunwin Stevia International, Inc., a Nevada corporation, and its subsidiaries are referred to in this report as “we”, “us”, "our”, or “Sunwin”. We changed our name from Sunwin Neutraceuticals International Inc. to Sunwin Stevia International, Inc. on April 23, 2012 to more accurately reflect our business operations.

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines and veterinary products. Substantially all of our operations are located in the People’s Republic of China (the “PRC”). We have built an integrated company with the sourcing and production capabilities designed to meet the needs of our customers.

Our operations are organized into two operating segments related to our Stevioside and Chinese Medicine product lines.

Stevioside Segment

In our Stevioside segment, we produce and sell a variety of purified steviol glycosides with rebaudioside A and stevioside as the principal components, an all natural, low calorie sweetener, and OnlySweet, a stevioside based table top sweetener.

Chinese Medicine Segment

In our Chinese Medicine Segment, we manufacture and sell a variety of traditional Chinese medicine formula extracts which are used in products made for use by both humans and animals.

Qufu Shengwang

In fiscal 2009, Qufu Natural Green acquired a 60% interest in Qufu Shengwang from its shareholder, Shandong Group, for $4,026,851. The purchase price represented 60% of the value of the net tangible assets of Qufu Shengwang as of April 30, 2008. Shandong Group is owned by Laiwang Zhang, our President and Chairman of the Board of Directors.  Qufu Shengwang manufactures and sells stevia -based fertilizers and feed additives.

On September 30, 2011, Qufu Shengwang purchased the 40% equity interest in Qufu Shengwang owned by our Korean partner, Korea Stevia Company, Limited, for $626,125 in cash, and as a result of this repurchase transaction we now own 100% equity interest in all of the net assets of our subsidiary Qufu Shengwang. Therefore, the non-controlling interest of $2,109,028 in our balance sheet as of April 30, 2012 has been eliminated to reflect our 100% interest in Qufu Shengwang. On July 1, 2012, Qufu Shengwang entered the Cooperation Agreement with Hegeng (Beijing) Organic Farm Technology Co, Ltd. (“Hegeng”), a Chinese manufacturer and distributor of bio-fertilizers and pesticides, to jointly develop bio-bacterial fertilizers based on the residues from our stevia extraction. Under the Cooperation Agreement, Hegeng provides strain and formula that we apply to the stevia residues to produce bio-bacterial fertilizers in the current facility of Qufu Shengwang. The bio-bacterial fertilizers will be distributed under Qufu Shengwang’s name.  No additional investment in the facility would be required. During the third quarter of fiscal 2013, we decided to suspend the agreement with Hegeng due to a lack of sales since the reaction to the products was lower than anticipated in fertilizer market. Currently we plan to use these assets to manufacture a variety of traditional Chinese medicine formula extracts. We expect to start production in fiscal 2014.

Qufu Shengren

In fiscal 2009, Qufu Natural Green acquired Qufu Shengren for $3,097,242. The purchase price was equal to the value of the assets of Qufu Shengren as determined by an independent asset appraisal in accordance with asset appraisal principles in the PRC. Prior to being acquired by us, Qufu Shengren was engaged in the production and distribution of bulk drugs and pharmaceuticals.  Subsequent to the acquisition, Qufu Shengren produces and distributes steviosides with a full range of grades from rebaudioside-A 10 to 98.

- 4 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

Sunwin USA

In fiscal 2009, we entered into a distribution agreement with WILD Flavors to assist our 55% owned subsidiary, Sunwin USA, in the marketing and worldwide distribution of our stevioside-based sweetener products and issued WILD Flavors a 45% interest in Sunwin USA.

On August 8, 2012, we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541.  The transaction closed on August 20, 2012. On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors.The $92,541 cash payment was paid by China Direct Investment, Inc. (“CDI”), our corporate management services provider, and reimbursed by us to CDI through the issuance of our common shares as part of the terms of the consulting agreement with CDI dated May 1, 2012. The net tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of generally accepted accounting principles (“U.S. GAAP”) which requires elimination of the difference between the purchase price of the 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets include the product development and supply chain for OnlySweet.

Under the terms of the agreement, WILD Flavors assumed certain pre-closing obligations of Sunwin USA totaling approximately $694,000, including trade accounts receivable, loans, health care and monthly expenses of an employee, potential chargebacks, bank fees and broker commissions incurred prior to the closing date. The agreement also contained customary joint indemnification and general releases.  As a result of this transaction, we began consolidating the operations of Sunwin USA from the date of acquisition (August 20, 2012).

In addition to the Exchange Agreement, on August 8, 2012 we entered into the following additional agreements with WILD Flavors or its affiliate:

•           We entered into an Amendment to Operating Agreement with WILD Flavors pursuant to which we are now the sole manager of Sunwin USA and certain sections of the original agreement dated April 29, 2009 were cancelled as they were no longer relevant following our purchase of the minority interest in Sunwin USA described above;

•           We entered into a Termination of Distribution Agreement with WILD Flavors and Sunwin USA pursuant to which the Distribution Agreement dated February 5, 2009 was terminated; and

•           We entered into a Distributorship Agreement with WILD Procurement Gmbh, a Swiss corporation (“WILD Procurement”) which is an affiliate of WILD Flavors. Under the terms of this agreement, we appointed WILD Procurement as a non-exclusive world-wide distributor for the resale of our stevia products.  There are no minimum purchase quantities under the agreement, and the pricing and terms of each order will be negotiated by the parties at the time each purchase order is placed.  The agreement restricts WILD Procurement from purchasing steviosides or other forms of stevia that are included in our products from sources other than our company under certain circumstances. In addition, at such time as we desire to offer new products, we must first offer WILD Procurement the non-exclusive right to distribute those products and the parties will have 60 days to reach mutually agreeable terms. The agreement contains certain representations by us as to the quality of the products we may sell WILD Procurement and the products’ compliance with applicable laws and good manufacturing practices, as well as customary confidentiality and indemnification provisions.

In the event WILD Procurement should fund research on stevia used in food, beverage or dietary supplement applications, and as a result of this research it develops new intellectual property, such intellectual property shall be the sole property of WILD Procurement. In the event we should jointly fund research, any new intellectual property developed from this effort will be jointly owned and each party will have the right to use the developed intellectual property in stevia-based products.

- 5 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

The agreement is for an initial term of 12 months and will automatically renew for successive 12 month terms unless the agreement has been terminated by either party upon 45 days prior written notice. There are no assurances any purchase orders will be placed under the terms of the Distribution Agreement. The agreement may also be terminated by either party upon a material breach by the other party, or upon the filing of a bankruptcy petition, both subject to certain cure periods. In the event the agreement is terminated, WILD Procurement has the right to continue to distribute our products on a non-exclusive basis for 24 months upon terms and conditions to be negotiated by the parties.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. The accompanying unaudited condensed consolidated financial statements for the interim periods presented are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented. Certain financial statement amounts relating to prior periods have been reclassified to conform to the current period presentation.

These unaudited condensed consolidated interim financial statements should be read in conjunction with the financial statements and footnotes for the year ended April 30, 2013 included in our Form 10-K as filed with the SEC. The results of operations and cash flows for the nine months ended January 31, 2014 are not necessarily indicative of the results of operations or cash flows which may be reported for future periods or the full fiscal year.

Our unaudited condensed consolidated financial statements include the accounts of Sunwin and all our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Our subsidiaries include the following:

- Qufu Natural Green;

- Qufu Shengren;

- Qufu Shengwang;

- Sunwin Tech; and

- Sunwin USA

As reflected in the accompanying unaudited condensed consolidated financial statements, during the first nine months of fiscal year 2014, the Company had a net loss of approximately $1.7 million and net cash provided by operations of $1.3 million. At January 31, 2014, we had working capital of $4.7million, including cash of $830,000. We believe the Company has the ability to further implement its business plan, raise additional capital, generate more revenues, and collect receivables from the third party and related parties to increase the working capital.

USE OF ESTIMATES

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates include the allowance for doubtful accounts, the allowance for obsolete inventory, the useful life of property and equipment and intangible assets, assumptions used in assessing impairment of long-term assets and valuation of deferred tax assets, and the value of stock-based compensation.  Actual results could differ from those estimates.

- 6 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of January 31, 2014, we held $825,525 of our cash and cash equivalents with commercial banking institutions in the PRC, and $4,510 with banks in the United States. As of April 30, 2013, we held $516,071 of our cash and cash equivalents with commercial banking institution in PRC, and $1,035 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through January 31, 2014.

ACCOUNTS RECEIVABLE

Accounts receivable and other receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At January 31, 2014 and April 30, 2013, the allowance for doubtful accounts was $1,134,102 and $1,000,291, respectively.

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method. An allowance is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected market value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the market value. These reserves are recorded based on estimates. At January 31, 2014 and April 30, 2013, the Company recorded a reserve for obsolete or slow-moving inventories of $971,178 and $954,108, respectively.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

LONG-LIVED ASSETS

In accordance with ASC Topic 360, we review and evaluate our long-lived assets, including property and equipment, intangible assets, and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates. Based on our evaluation, for the three and nine months ended January 31, 2013, we recorded an impairment loss of $209,194 and $209,194, related to impairment of the carrying amounts certain machinery and equipment deemed unusable, respectively.

- 7 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC 820-10-35-37 to measure the fair value of our financial instruments. ASC 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at January 31, 2014 and April 30, 2013 amounted to $13,801 and $0, respectively, consisting primarily of VAT taxes payable.

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

GRANT INCOME

Grants received from PRC government agencies are recognized as deferred grant income and recognized in the consolidated statements of operations as and when they are incurred for the specific research and development projects or general operation purpose for which these grants are received.

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns.

- 8 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

We apply the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our consolidated financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of January 31, 2014, the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

BASIC AND DILUTED LOSS PER SHARE

Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations. The following table presents a reconciliation of basic and diluted net income per ordinary share:

	Three Months Ended January 31,						Nine Months Ended January 31,
	2014			2013			2014			2013
Net loss allocable to common shareholders for basic and diluted net loss per common share	$	(166,062	)	$	(826,841	)	$	(1,709,446	)	$	(3,064,956	)
Weighted average common shares outstanding - basic		173,882,803			173,374,671			173,882,803			165,946,391
Effect of dilutive securities:
Warrants		-			-			-			-
Weighted average common shares outstanding – diluted		173,882,803			173,374,671			173,882,803			165,946,391
Net loss per common share - basic	$	(0.001	)	$	(0.005	)	$	(0.009)		$	(0.018	)
Net loss per common share - diluted	$	(0.001	)	$	(0.005	)	$	(0.009)		$	(0.018	)

For the three and nine months ended January 31, 2014 and 2013, the effect of 26,666,666 outstanding common stock purchase warrants were anti-dilutive as we reported a net loss applicable to our common shareholders for both periods., and these outstanding purchase warrants re anti-dilutive as the exercise price of the warrants exceeded the average market price.  As a result, basic loss per share was equal to diluted loss per share for the three and nine months ended January 31, 2014 and 2013.

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company is the U.S. dollar and the functional currency of the Company’s operating subsidiaries is the Chinese Renminbi (“RMB”).  In accordance with ASC 830-20-35, the consolidated financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements and cash flows. Equity accounts were stated at their historical rate. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

- 9 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2013	RMB 6.21 to $1.00
As of January 31, 2014	RMB 6.10 to $1.00
Nine months ended January 31, 2014	RMB 6.15 to $1.00
Nine months ended January 31, 2013	RMB 6.30 to $1.00

CONCENTRATIONS OF CREDIT RISK

Substantially all of our operations are carried out in the PRC. Accordingly, our business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC’s economy. Our operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. Our results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At January 31, 2014, we had $825,525 on deposit in China, which is not insured. We have not experienced any losses in such accounts through January 31, 2014.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

STOCK-BASED COMPENSATION

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of ASC Topic 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). “FASB” ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company records compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated, based on the then current fair value, at each subsequent reporting date.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying consolidated statements of operations. Research and development costs are incurred on a project specific basis. Research and development costs were $24,343 and $64,541 for the nine months ended January 31, 2014 and 2013, respectively.

- 10 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

RECENT ACCOUNTING PRONOUNCEMENTS

In March 2013, the FASB issued ASU 2013-05 “Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity.” ASU 2013-05 addresses the accounting for the cumulative translation adjustment when a parent either sells part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. For public entities, the ASU is effective prospectively for fiscal years, and interim periods, within those years, beginning after December 15, 2013. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on the Company’s consolidated financial statements.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

NOTE 3 - INVESTMENT IN REAL ESTATE HELD FOR RESALE

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units were expected to be delivered by December 30, 2012. As of January 31, 2014, we are processing the deed and other legal documents for the apartment; the apartment units are expected to be delivered by the fourth quarter of fiscal year 2014. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance of approximately $478,066 due upon completion of the ownership documents and transfer of the apartment units to us. As of January 31, 2014 and April 30, 2013, we classified investment in real estate held for resale as a long-term asset since we do not plan on selling the apartment units within one year. As of January 31, 2014 and April 30, 2013, investment in real estate held for resale amounted to $1,981,879 and $1,947,042, respectively.

NOTE 4 - INVENTORIES

At January 31, 2014 and April 30, 2013, inventories consisted of the following:

	January 31, 2014			April 30, 2013
	(Unaudited)
Raw materials	$	1,149,987		$	1,099,001
Work in process		863,664			659,631
Finished goods		3,786,673			4,123,447
		5,800,324			5,882,079
Less: reserve for obsolete inventory		(971,178	)		(954,108	)
	$	4,829,146		$	4,927,971

- 11 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

NOTE 5 - PROPERTY AND EQUIPMENT

At January 31, 2014 and April 30, 2013, property and equipment consisted of the following:

	Estimated Life	January 31, 2014			April 30, 2013
		(Unaudited)
Office Equipment	5-7 Years	$	55,282		$	48,741
Auto and Trucks	10 Years		936,520			907,480
Manufacturing Equipment	20 Years		12,083,165			11,687,057
Buildings	20 Years		10,401,306			10,192,769
Construction in Process			734,772			668,330
			24,211,045			23,504,377
Less: Accumulated Depreciation			(9,274,412	)		(7,778,993	)
		$	14,936,633		$	15,725,384

For the nine months ended January 31, 2014 and 2013, depreciation expense totaled $1,346,728 and $1,240,136, respectively. Depreciation is not taken during the period of construction or equipment installation. Upon completion of the installation of manufacturing equipment or any construction in progress, construction in progress balances will be classified to their respective property and equipment category.

NOTE 6 - INTANGIBLE ASSETS

On August 8, 2012 the Company entered into an Exchange Agreement with WILD Flavors pursuant to which it purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541. In connection with the Exchange Agreement, WILD Flavor granted, transferred and assigned to Sunwin USA all of its rights, title and interest, and the trade name Only Sweet, including any trademarks, trademark registrations and applications, service marks, service mark registrations and applications, copyrights, copyright registrations and applications, trade dress, trade names (whether or not registered or by whatever name or designation), owned, applied for, or registered in the name of, the WILD Flavor (the "Only Sweet Name Rights"). Additionally, we entered into a new Distributorship Agreement with WILD Procurement which is an affiliate of WILD Flavors, as discussed in Note 1. The transaction closed on August 20, 2012. The tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of U.S. GAAP which requires elimination of the difference between the purchase price of the 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets have a useful life of five years and consist of the cost of Only Sweet Name Rights and related technologies as well as the fair value of the Wild Flavors distribution Agreement. For the nine months ended January 31, 2014 and 2013, amortization expense amounted to $243,881 and $135,490, respectively.

            Intangible assets consisted of the following:

	Estimated Life	January 31, 2014			April 30, 2013
		(Unaudited)
Only Sweet name rights and related technologies	5 Years	$	587,183		$	587,183
Distribution agreement and related distribution channels	5 Years		1,038,691			1,038,691
			1,625,874			1,625,874
Less: accumulated amortization			(460,665	)		(216,784	)
Intangible Assets, net		$	1,165,209		$	1,409,090

- 12 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

NOTE 7 - LAND USE RIGHTS

Land use right consisted of the following:

	Estimated Life	January 31, 2014			April 30, 2013
		(Unaudited)
Land use right	41-65 Years	$	2,605,862		$	2,559,545
Less: accumulated amortization			(318,227	)		(270,001	)
		$	2,287,635		$	2,289,544

 In conjunction with our acquisition of Qufu Shengwang, we acquired land use rights for properties located in the PRC until March 14, 2054. For the nine month ended January 31, 2014 and 2013, amortization expense amounted to $43,090 and $42,022, respectively.

NOTE 8 - LOAN RECEIVABLE

On December 22, 2010, we loaned $500,000 to CDI China, Inc., a subsidiary of CD International Enterprises, Inc., and an affiliate of CDI our corporate management services provider. The loan bears interest at the rate of 3% per annum and the principal balance and accrued interest were due March 30, 2011. Principal balance of $305,459 was repaid and part of accrued interest of $171,720 was repaid to us by CDI China, Inc. during fiscal 2012 and 2013. As of January 31, 2014, CDI China, Inc. repaid all remaining principal balances and accrued interest.

NOTE 9 - RELATED PARTY TRANSACTIONS

Accounts receivable – related party

At January 31, 2014 and April 30, 2013, we reported $644,448 and $1,239,222 in accounts receivable – related party, respectively.  Accounts receivable – related party reflected amounts due from Qufu Shengwang Import and Export Corporation, a Chinese entity owned by our Chairman, Mr. Laiwang Zhang, for merchandise that has been delivered. For the three months ended January 31, 2014 and 2013, related party revenues were $833,657 and $171,547, respectively. For the nine months ended January 31, 2014 and 2013, related party revenues were $2,567,648 and $1,576,463, respectively.

Due to (from) related parties

From time to time, we received advances from related parties and advanced funds to related parties for working capital purposes. The advances bear no interest and are payable on demand.  For the nine months ended January 31, 2014, due to (from) related party activities consisted of the following: 

	Pharmaceutical Corporation			Qufu Shengwang Import and Export			Total
Balance due to related parties, April 30, 2013	$	110,018		$	64,386		$	174,404
Working capital advances from related parties		305,509			249,220			554,729
Repayments		(195,624	)		(313,606	)		(509,230	)
Effect of foreign currency exchange		980			-			980
Balance due from related parties, January 31, 2014	$	220,883		$	-		$	220,883

- 13 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

NOTE 10 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets at January 31, 2014 and April 30, 2013 totaled $1,300,365 and $1,189,416, respectively. As of January 31, 2014, prepaid expenses and other current assets includes $929,656 of prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us; $178,274 for employee advances and a $192,435 deposit for renewing land use rights. During the third quarter of fiscal 2013, Qufu Shengwang paid Qufu Public Auction Center $608,920 as deposit for renewing the land use right. The deposit is required for the Center to do the appraisal of the land use right. In the fourth quarter of fiscal 2013 and in the third quarter of fiscal 2014, we received a refund of this deposit of $388,631 and $27,854, respectively.

As of April 30, 2013, prepaid expenses and other current assets includes $718,437 of prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us; $159,149 for employee advances; $95,413 of prepaid VAT and a $216,417 in a deposit for renewing land use rights.

 NOTE 11 – GRANT INCOME

Deferred grant income at January 31, 2014 and April 30, 2013 totaled $764,614 and $0, respectively. On January 26, 2014, we received grant funding of $1,146,921 (RMB 7,000,000), in exchange for commitments made by us to the local government of Qufu city to provide research and development for the planting of stevia plants, for the development of biological methods to improve lower-grade stevia product to higher grade stevia, and applying biological method to change the taste of stevia to meet market demand. The grant term is for three years, from January 1, 2013 through December 2015. Deferred grant income is being amortized as an increase to other income and amortized over a 3-year period by straight line method from January of 2013.

NOTE 12 - LOAN PAYABLE

In March 18, 2013, we entered to a loan agreement for approximately $809,822 (RMB 5,000,000) with China Construction Bank. According to the terms of the agreement with China Construction Bank, the loan bears interest at the rate of 7.8% per annum and the principal balance with accrued interest was due on March 17, 2014. We repaid the principal amounts of the loan with all accrued interest in January 2014.  At January 31, 2014 and April 30, 2013, loans payable amounted to $0 and $804,829, respectively.

NOTE 13 - STOCKHOLDERS' EQUITY

Common stock

At January 31, 2014, we are authorized to issue 200,000,000 shares of common stock. We had 173,882,803 and 173,882,803 shares outstanding at January 31, 2014 and April 30, 2013, respectively.

Common stock purchase warrants

A summary of the changes to our outstanding stock warrants during the nine months ended January 31, 2014 is as follows:

	Shares		Weighted Average  Exercise Price
Outstanding at April 30, 2013		26,666,666	$	0.35
Granted		-		-
Exercised		-		-
Forfeited		-		-
Warrants exercisable at January 31, 2014 (unaudited)		26,666,666	$	0.35

- 14 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

Common stock purchase warrants (continued)

The following information applies to all warrants outstanding at January 31, 2014:

		Warrants Outstanding						Warrants Exercisable
	Exercise Prices	Shares		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Shares		Weighted Average Exercise Price
$	0.35		26,666,666		0.01	$	0.35		26,666,666	$	0.35
			26,666,666			$	0.35		26,666,666	$	0.35

NOTE 14 - SEGMENT INFORMATION

    The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three and nine months ended January 31, 2014 and 2013; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2014 and 2013 is as follows:

	Three Months Ended January 31,				Nine Months Ended January 31,
	2014		2013		2014		2013
Revenues:
Chinese medicine – third party	$	713,896	$	1,111,530	$	1,862,718	$	2,475,830
Chinese medicine – related party		-		-		-		-
Total Chinese medicine		713,896		1,111,530		1,862,718		2,475,830
Stevioside – third party		1,680,795		687,414		4,338,845		3,615,509
Stevioside – related party		833,657		171,547		2,567,648		1,576,463
Total Stevioside		2,514,452		858,961		6,906,493		5,191,972
Total segment and consolidated revenues	$	3,228,348	$	1,970,491	$	8,769,211	$	7,667,802

Interest income (expense):
Chinese medicine	$	92		$	1,667		$	370		$	1,733
Stevioside		(35,573	)		(1,030	)		(69,101	)		4,719
Corporate and other		-			-			-			1,718
Total segment and consolidated interest income (expense)	$	(35,481	)	$	637		$	(68,731	)	$	8,170
Depreciation and amortization:
Chinese medicine	$	31,963		$	19,811		$	77,996		$	59,197
Stevioside		432,169			532,909			1,311,822			1,358,451
Corporate and other		81,294			-			243,881			-
Total segment and consolidated depreciation and amortization	$	545,426		$	552,720		$	1,633,699		$	1,417,648

- 15 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

	Three Months Ended January 31,						Nine Months Ended January 31,
	2014			2013			2014			2013
(Loss) income before income taxes:
Chinese medicine	$	98,689		$	137,625		$	47,689		$	149,002
Stevioside		(238,493	)		(806,192	)		(1,705,763	)		(1,495,243	)
Corporate and other		(26,258	)		(161,718	)		(51,198	)		(1,718,715	)
Total consolidated (loss) income before income taxes	$	(166,062	)	$	(830,285	)	$	(1,709,272	)	$	(3,064,956	)

	January 31, 2014		April 30, 2013
Segment tangible assets:
Chinese medicine	$	648,711	$	644,073
Stevioside		14,287,922		15,081,311
Corporate and other		-		-
Total consolidated assets	$	14,936,633	$	15,725,384

NOTE 15 - COMMITMENTS AND CONTINGENCIES

We lease office and manufacturing space under leases in Shandong, China that expire through 2014.

All facilities related to traditional Chinese medicine segment are leased from Pharmaceutical Corporation, a related party. The term of this lease expired in October, 2012 and provides for annual lease payments of $23,400. We paid the rent for this facility in fiscal 2012 which was included in the management fee we paid to Pharmaceutical Corporation during fiscal 2012. After October 1, 2012 Pharmaceutical Corporation agreed to waive the lease payments.

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units were expected to be delivered by December 30, 2012. As of April 30, 2014, we did not receive the deed and other legal documents for the apartment because the local government did not finish inspection; the company does not know when the apartment units can be delivered. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066 due upon completion of the ownership documents and transfer of the apartment units to us. As January 31, 2014 and April 30, 2013, we classified investment in real estate held for resale as a long-term asset since we do not plan on selling the apartment units within one year. As of January 31, 2014 and April 30, 2013, investment in real estate held for resale amounted to $1,981,879 and $1,947,042, respectively.

- 16 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

January 31, 2014

NOTE 16 - CONCENTRATIONS AND CREDIT RISK

(i)    Customer Concentrations

For the nine months ended January 31, 2014 and 2013, customers accounting for 10% or more of the Company’s revenue were as follows:

	Net Revenues
	For the nine months ended January 31, 2014				For the nine months ended January 31, 2013
	Chinese Medicine		Stevioside		Chinese Medicine		Stevioside
Qufu Shengwang Import and Export Trade Co., Ltd (1)		-		41.2%		-		46.0%
Guangdong Tengjun Veterinary Medicine Co., Ltd		-		-		11.6%		-
Total		-		41.2%		11.6%		46.0%

(1) Qufu Shengwang Import and Export Trade Co., Ltd is a related party, a Chinese entity managed by our Chairman, Mr. Laiwang Zhang.

(ii)    Vendor Concentrations

For the nine months ended January 31, 2014 and 2013, suppliers accounting for 10% or more of the Company’s purchase were as follows:

	Net Purchases
	For the nine months ended January 31, 2014					For the nine months ended January 31, 2013
	Chinese Medicine		Stevioside			Chinese Medicine			Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd	16.7	%		-			38.1	%		-
Qufu Longheng Materials Co., Ltd	18.7	%		-			34.9	%		-
Jiuquan Jiale Biotech Co., Ltd	-			-			-			20.0	%
Gansu Fanzhi Biology Technology Co.,Ltd	17.2	%		-			-			-
Qingdao Runhao Stevia Technology Co., Ltd	-			-			-			13.0	%
Total	52.6	%		-	%		73.0	%		33.0	%

(iii)    Credit Risk

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and the PRC. At January 31, 2014, we had $825,525 on deposit in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash held in PRC financial institutions is not insured. We have not experienced any losses in such accounts through January 31, 2014.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

NOTE 17 - SUBSEQUENT EVENTS

The Company has evaluated subsequent events from January 31, 2014 through the date whereupon the financial statements were issued and has determined that there are no items to disclose.

- 17 -

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the preceding unaudited condensed consolidated financial statements and footnotes. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended April 30, 2013 as filed with the Securities and Exchange Commission.  We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

OVERVIEW

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines. Substantially all of our operations are located in the PRC. We have built an integrated company with the production and distribution capabilities designed to meet the needs of our customers.

During fiscal 2014 and 2013, our operations were organized in two operating segments related to our product lines:

- Stevioside, and

- Chinese Medicine.

Stevioside Segment

Stevioside and rebaudioside are all natural low calorie sweeteners extracted from the leaves of the stevia rebaudiana plant. Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets. Stevioside can be used to replace sugar in beverages and foods, including those that require baking or cooking where synthetic chemical based sweetener replacements are not suitable.

Steviosin is a natural low calorie stevioside extract for medicinal use, containing rebaudioside A at 90% with the total steviol glycosides meeting or exceeding 95% on a dry weight basis. Steviosin is used as an alternative sweetener in the pharmaceutical production in China.

OnlySweet™ is an all natural, zero calorie, dietary supplement comprised of three natural ingredients, including stevioside.  Based on our strategy to develop new products that contain our stevia products, we are evaluating our strategy for the sale and distribution of OnlySweet™.

In an effort to meet the international food safety standards mandated by larger consumer product companies that we expect to target as customers in the future, we have made capital investments to enhance our manufacturing facilities, equipment and documentation systems, changed certain manufacturing processes and carried out additional personnel training in order to meet these standards.  These investments allowed us to meet the HACCP System Certification, ISO 9001:2008 Certification and ISO 22000:2005 Food Safety Certification. We obtained these certifications in November, 2010.

Chinese Medicine Segment

In our Chinese medicine segment, we manufacture and sell approximately 354 different extracts, which can be divided into the following three general categories:

- single traditional Chinese medicine extracts;

- compound traditional Chinese medicine extracts; and

- purified extracts, including active parts and monomer compounds such as soy isoflavone.

Three and nine months ended January 31, 2014 compared to the comparable period in 2013

 Our total revenues in the third quarter of fiscal 2014 increased by 63.8%, from the same period in fiscal 2013, while our gross margin increased to 21.0% from 20.2% compared to the same period in fiscal 2013. Our sales revenues, excluding revenues from related party, increased by 33.1% in the third quarter of fiscal 2014 as compared to the same period in fiscal 2013. Revenues from related parties increased 386.0% in the third quarter of fiscal 2014 from the comparable period in fiscal 2013. Our operating expenses in the third quarter of fiscal 2014 decreased by 2.3% from the comparable period in 2013. Our net loss for the third quarter of fiscal 2014 was $166,000, as compared to $827,000 for the same period in fiscal 2013. 

- 18 -

Our total revenue for the first nine months of fiscal 2014 increased by 14.4% from the same period in fiscal 2013, while our gross margin decreased to 16.3% from 19.0% over the same period in fiscal 2013. Our sales revenues, excluding revenues from related party, increased by 1.8%, in the first nine months of fiscal 2014 as compared to the same period in fiscal 2013. Our operating expenses during the first nine months of fiscal 2014 decreased by 21.3% compared with the same period in fiscal 2013. Our net loss for the first nine months of fiscal 2014 was $1.7 million, compared to $3.1million for the same period in fiscal 2013.

Our operating performance for the nine months ended January 31, 2014was primarily driven by an expected increase in sales revenue attributable to increase export sales volume and our new product sales volume for higher grades stevia products in our Stevioside segment and lower revenues in our Chinese medicine segment. The increase of sales to related party is primarily due to the expansion of our international business and increase new product sales in higher grades stevia products. Since we do not have the authorization to export products from China, we outsourced all of our exporting business to our certified related party Qufu Shengwang Import and Export Corporation. We did not have any sales to related parties in our Chinese medicine segment in either period.

Total revenues for the first nine months of fiscal 2014 increased 14.4% as compared to the same period in fiscal 2013. Stevioside revenues, which comprised 78.8% and 67.7% of our revenues for the first nine months of fiscal 2014 and fiscal 2013, respectively, increased by 33.0% while revenues in our Chinese Medicine segment decreased by 24.8%.

While we have broadened our stevia product offerings to include a number of higher quality stevia grades which are needed in new product formulations we are developing to introduce to the U.S. and European food and beverage market, the demand for higher grade stevia products has yet to materialize to the degree we had anticipated, and thus our sales volume in higher grade stevia products was lower than expected during the fiscal 2014 and 2013 periods. The increase of revenue in Stevioside segment is primarily due to a developing the domestic and international market. Stevia has been widely accepted by food industry and many new stevia manufacturers have entered this industry in the past few years, and recently we introduced a new product line. We are now focusing on new types of stevia products, including tablets, liquid, High A products, and others. We expect to consistently increase our sales of our new products; however we cannot quantify this increase and its effects on future periods.

The decrease in revenues in our Chinese medicine was primarily due to the depressing market which was caused by the significantly declined production of farms, negatively influencing the demand for our Chinese traditional medicine products since 2012. In addition, the suppliers of some large farms have innovated to operate on the integrative basis, and the monopolized use of medicine, both lead to the decreased demand to our products. Some big clients of ours have changed to produce their own Chinese herbal extracts products; therefore, the orders from those big clients have decreased significantly. Our current orders primarily are low-volume and have mix-varieties. The lost of high volume orders greatly impacted our total sales.

Our Outlook

We believe that there are significant opportunities for worldwide growth in our Stevioside segment, primarily in the U.S. and EU. For fiscal 2014 and beyond, we will continue to focus on our core business of producing and selling stevioside series products. Meanwhile, we are also facing challenges in competitive pricing and raw materials for fiscal 2014. During fiscal 2013, the market prices of stevioside series were impacted by strong price competition among Chinese manufacturers. We expect the price pressure to continue in fiscal 2014. We anticipate the price of stevia leaves, the raw material used to produce our stevioside series products to increase in the coming harvest fall season for calendar year 2013.

- 19 -

RESULTS OF OPERATIONS

The following table summarizes our results from operations for the three month periods ended January 31, 2014 and 2013:  

January 31, 2014
		Chinese Medicine					Stevioside					Corporate and other			Consolidated
Total revenues	$	713,896		100.0	%	$	2,514,452		100.0	%	$	-			3,228,348		100.0	%
Cost of revenues		447,367		62.7	%		2,102,627		83.6	%		-			2,549,994		79.0	%
Gross profit		266,529		37.3	%		411,825		28.3	%		-			678,354		21.0	%
Total operating expenses		163,125		22.9	%		990,895		39.4	%		26,258			1,180,278		36.6	%
Other income (expenses)		(4,715	)	-	%		340,577		13.5	%		-			335,862		10.4	%
Income (loss) before income taxes	$	98,689		13.8	%	$	(238,493	)	-9.5	%	$	(26,258	)	$	(166,062	)	-5.1	%

January 31, 2013
		Chinese Medicine				Stevioside					Corporate and other			Consolidated
Total revenues	$	1,111,530	100.0	%	$	858,961		100.0	%	$	-			1,970,491		100.0	%
Cost of revenues		957,389	86.1	%		615,372		71.6	%		-			1,572,761		79.8	%
Gross profit		154,141	13.9	%		243,589		28.4	%		-			397,730		20.2	%
Total operating expenses		16,631	1.5	%		1,030,099		119.9	%		161,718			1,208,448		61.3	%
Other income (expenses)		115	-	%		(19,682)		-2.3	%		-			(19,567	)	-1.0	%
Income (loss) before income taxes	$	137,625	12.4	%	$	(806,192	)	-93.9	%	$	(161,718	)	$	(830,285	)	-42.1	%

The following table summarizes our results from operations for the nine month periods ended January 31, 2014 and 2013: 

January 31, 2014
	Chinese Medicine					Stevioside					Corporate and other			Consolidated
Total revenues	$	1,862,718		100.0	%	$	6,906,493		100.0	%	$	-		$	8,769,211		100.0	%
Cost of revenues		1,200,626		64.5	%		6,143,597		89.0	%		-			7,344,224		83.8	%
Gross profit		662,091		35.5	%		762,896		11.1	%		-			1,424,987		16.3	%
Total operating expenses		616,286		33.1	%		2,768,430		440.1	%		167,676			3,552,386		40.5	%
Other income		1,883		-	%		299,766		4.3	%		116,478			418,127		4.8	%
Loss before income taxes	$	(47,689	)	-2.6	%	$	(1,705,768	)	-24.7	%	$	(51,198	)	$	(1,709,272	)	-19.5	%

- 20 -

January 31, 2013
	Chinese Medicine					Stevioside				Corporate and other				Consolidated
Total revenues	$	2,475,830	100.0	%	$	5,191,972		100.0	%	$	-		$	7,667,802		100.0	%
Cost of revenues		2,003,326	80.9	%		4,209,260		81.1	%		-			6,212,586		81.0	%
Gross profit		472,504	19.1	%		982,712		18.9	%		-			1,455,216		19.0	%
Total operating expenses		323,736	13.1	%		2,468,620		47.6	%		1,720,433			4,512,789		58.9	%
Other income		234	-	%		(9,335	)	-0.2	%		1,718			(7,383	)	-0.1	%
Income (loss) before income taxes	$	149,002	6.0	%	$	(1,495,243	)	-28.8	%	$	(1,718,715	)	$	(3,064,956	)	-40.0	%

Revenues

Total consolidated revenues in the third quarter of fiscal 2014 increased 63.8% as compared to the same period in fiscal 2013. Stevioside revenues, which comprised 77.9% and 43.6% of our revenues for the third quarter of fiscal 2014 and fiscal 2013, respectively, increased by 192.7%, while revenues in our Chinese Medicine segment decreased by 35.7%. Within our Stevioside segment, revenues from sales to third parties increased by 144.5% in the third quarter of fiscal 2014 from the third quarter of fiscal 2013, while revenues from sales to a related party increased by 386.0% in the comparable period. The increase of sales to related party is primarily due to the expansion of our international business and increase new product sales in higher grades stevia products. Since we do not have the authorization to export products from China, we outsourced all of our exporting business to our certified related party Qufu Shengwang Import and Export Corporation. We did not have any sales to related parties in our Chinese medicine segment in either period.

Total revenues for the first nine months of fiscal 2014 increased 14.4% as compared to the same period in fiscal 2013. Stevioside revenues, which comprised 78.8% and 67.7% of our revenues for the first nine months of fiscal 2014 and fiscal 2013, respectively, increased by 33.0%, while revenues in our Chinese Medicine segment decreased by 24.8%. Within our Stevioside segment, revenues from sales to third parties increased by 20.0% for the first nine months of fiscal 2014 from the same period of fiscal 2013, while revenues from sales to a related party increased by 62.9% in the comparable period.

The revenues in Stevioside segment increased by 33.0% for the first nine months of fiscal 2014 as compared to the first nine months of fiscal 2013 which is attributable to the increase by 62.9% in sales the related party and increase by 27.2% in sales volume was offset by a decline in the unit sale price of our Stevioside products which decreased as compared to the same period of prior year. The unit sale price declined as a result of the competitive market. Particularly, the unit sale price of new product declined approximately 20%.  We generated revenue from the customized orders for restructuring by enzyme based on our Stevioside products which accounted for approximately 2.9% of total Stevioside segment revenues. Additionally, we also generated revenue from the sale of our new products that were developed in the prior year which accounted for approximately 8.0% of total consolidated revenues.

The decrease of sales in Chinese Medicine segment is primarily due to an approximately 6.7% decrease in our selling price and a 10.5% increase in sales volume. This decrease was attributable to an oversupply of product in the market. We expect demand to increase in future quarters; however, we are not able to quantify this future increase.

- 21 -

Cost of Revenues and Gross Margin

 The consolidated gross margin in the third quarter of fiscal 2014 increased to 21.0%, compared to 20.2% for the same period in fiscal 2013. Gross margin on Stevioside segment decreased during the third quarter of fiscal 2014 to 16.4%, compared to 28.4% for the same period in fiscal 2013. The decrease was primarily due to the decrease in our sales price as discussed above and from an increase of approximately 12% in raw material costs used in the production of Stevioside.Additionally, in connection with the sale of our new products we recognized a gross loss of approximately $60,000 attributable to the allocation of fixed costs to low productions levels which contributed to our lower gross margins.We expect to recognize gross margins on our new products as we increase sales and increase production levels, The Chinese medicine gross margin increased to 37.3% in the third quarter of fiscal 2014, compared to 13.9% for the same period in fiscal 2013. This increase in gross margin was due primarily due to lower raw material costs during the period compared with the same period in the prior year.  We believe that the slower market for animal Chinese medicines seen in prior periods has stabilized and the market has improved.

The consolidated gross margin for the first nine months of fiscal 2014 decreased to 16.3%, compared to 19.0% for the same period in fiscal 2013. Gross margin on Stevioside segment decreased during the first nine months of fiscal 2014 to 11.1%, compared to 18.9% for the same period in fiscal 2013. The decrease was primarily due to the increase of approximately 46.0% in cost of revenues.The Chinese medicine gross margin increased to 35.5% in the first nine months of fiscal 2014, compared to 19.1% for the same period in fiscal 2013, due to similar reasons discussed above. 

Total Operating Expenses

Total operating expenses for the third quarter of fiscal 2014 slightly decreased by 2.3% from the comparable period in 2013. The decrease was primarily due to a decrease of $209,000 in loss on disposition of equipment, a decrease of $188,000 in stock based compensation, offset by an increase of $269,000 in general and administrative expenses (consisting an increase in office expense of $118,000, an increase in salaries and wages of $130,000 and an increase in meal and entertainment of $51,000) and an increase of $100,000 in selling expenses which was attributable to an increase in marketing expenses related to our new products. Selling expenses as a percentage of revenues was 11.2% in the third quarter of fiscal 2014 as compared to 13.3% in the third quarter of fiscal 2013. General and administrative expenses as a percentage of revenues were 25.4% in the third quarter of fiscal 2014 as compared to 28.0% in the third quarter of fiscal 2013.

Total operating expenses for the first nine months of fiscal 2014 decreased by 21.3% from the comparable period in 2013. The decrease was primarily due to a decrease of $315,000 in general and administrative expenses (consisting a decrease in compensation paid to administrative management and certain of our employees of $810,000, a decrease in management fees of $429,000, offset an increase in bad debt of $386,000, an increase in office expense of $147,000, an increase in amortization  expenses of $144,000 and an increase in rent of $142,000); a decrease of $209,000 in loss on disposition of equipment and an decrease of $615,000 in stock based compensation, and offset by a $178,800 increase in the selling expenses. Selling expenses as a percentage of revenues was 10.6% in the first nine months of fiscal 2014 as compared to 9.8% in the same period of fiscal 2013. The general and administrative expense as a percentage of revenue was 29.9% in the first nine months of fiscal 2014 as compared to 38.3% in the same period of fiscal 2013.

Other Income (Expenses)

For the three months ended January 31, 2014, other income amounted to approximately $336,000 as compared to other expense of ($19,600) for the same period ended January 31, 2013. For the three months ended January 31, 2014, other income was primarily attributable to grant income of $382,000 related to a local PRC grant received in January 2014 of approximately $1,146,921 (RMB7,000,000), offset the increased interest expense. In March 18, 2013, we borrowed $809,822 (RMB 5,000,000) from a commercial bank under a loan and we paid off in the third quarter of fiscal 2014. We used the proceeds for working capital.

For the nine months ended January 31, 2014, other income amounted to approximately $418,000 as compared to other expense of ($7,400) for the same period ended January 31, 2013. The increase was primarily attributable to refund of a customs tariff during the nine months ended January 31, 2014 and an increased of grant income we discussed above.

- 22 -

Net Loss

Net loss for the third quarter of fiscal 2014 was approximately $166,000, compared to $827,000 in the same period in fiscal 2013. The decrease in net loss was primarily due to an increase in gross profit and grant income, and offset a decrease in operating expenses as discussed above.

Net loss from operations in the first nine months of fiscal 2014 was $2.1 million, compared to $3.1 million for the same period in fiscal 2013. The decrease in net loss was primarily due to decrease in gross profit and operating expenses as discussed above.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate sufficient cash to meet its operational cash requirements.  

At January 31, 2014, we had working capital of $4.7 million, including cash of $830,000, as compared to working capital of $5.0 million and cash of $517,000 at April 30, 2013. We believe that our existing cash and cash equivalents and internally generated funds will be sufficient to cover working capital requirements and capital expenditures for the fiscal year.       

Accounts receivable, net of allowance for doubtful accounts, including accounts receivable from related parties, decreased by approximately $811,000 during the nine months ended January 31, 2014. The days’ sales outstanding in accounts receivable decreased to 67 days as of January 31, 2014, as compared to 71 days as of October 31, 2013.

At January 31, 2014 inventories, net of reserve for obsolescence, totaled $4,829,000, as compared to $4,928,000 as of April 30, 2013. The decrease is primarily due to decrease of finished goods inventory and an increase in raw materials inventory in our stevioside business as we adjusted our production levels in anticipation of higher overseas and domestic demand in fiscal year 2014.

From time to time we received advances from related parties and advanced funds to related parties for working capital purposes. The advances bear no interest and are payable on demand.  For the nine months ended January 31, 2014, due to (from) related party activities consisted of the following: 

	Pharmaceutical Corporation			Qufu Shengwang Import and Export			Total
Balance due to related parties, April 30, 2013	$	110,018		$	64,386		$	174,404
Working capital advances from related parties		305,509			249,220			554,729
Repayments		(195,624	)		(313,606	)		(509,230	)
Effect of foreign currency exchange		980			-			980
Balance due to related parties, January 31, 2014	$	220,883		$	-		$	220,883

Our accounts payable and accrued expenses were approximately $3.3 million at January 31, 2014, a decrease of $316,000 from April 30, 2013. The change was primarily due to the timing of payments for payable balances related to raw material purchases made in the ordinary course of business.

- 23 -

Deferred grant income at January 31, 2014 and April 30, 2013 totaled $764,614 and $0, respectively. On January 26, 2014, we received grant funding of $1,146,921 (RMB 7,000,000), in exchange for commitments made by us to the local government of Qufu city to provide research and development for the planting of stevia plants, for the development of biological methods to improve lower-grade stevia product to higher grade stevia, and applying biological method to change the taste of stevia to meet market demand. The grant term is for three years, from January 1, 2013 through December 2015. Deferred grant income is being amortized as an increase to other income and amortized over a 3-year period by straight line method from January of 2013.

Cash Flows Analysis

NET CASH FLOW PROVIDED BY (USED IN) OPERATING ACTIVITIES:

Net cash provided by operating activities was approximately $1,302,000 during the first nine months of fiscal 2014, as compared to net cash used in operating activities of $2,472,000 during the same period in fiscal 2013. For the nine months ended January 31, 2014, cash flows provided by operations was primarily attributable to a decrease in account receivable of $171,000, a decrease in accounts receivables for the sales to related party of $613,000 and an increase in deferred grant income of $759,000 offset be a decrease in accounts payable and accrued expenses of $392,000.

Net cash used in operating activities was $2.5 million during the first nine months of fiscal 2013. For the nine months ended January 31, 2013, net cash used in operating activities was attributable to an increase in accounts receivable – related party of $175,000, an increase in inventories of $968,000, an increase in prepaid and other current assets of $938,000, an increase in due from related party of $792,000, an increase in tax receivable of $136,000 and a decrease in accounts payable and accrued expenses of $263,000 offset by a decrease in accounts receivable of $983,000 due to cash collection during the quarter.

NET CASH FLOW USED IN INVESTING ACTIVITIES:

Net cash used in investing activities amounted to $230,200 during the first nine months of fiscal 2014, as compared to net cash used in $757,900 for the same period in fiscal 2013. During the first nine months of fiscal 2014, we used cash of $273,800 for the purchase of property and equipment offset by $43,600 in proceeds received from loan receivable.

Net cash used in investing activities amounted to $0.8 million during the first nine months of fiscal 2013. During the first nine months of fiscal 2013, we used cash of $2,677,000 for the purchase of property and equipment offset by $1,921,000 in proceeds received from loan receivable.

NET CASH FLOW (USED IN) PROVIDED BY FINANCING ACTIVITIES:

Net cash used in financing activities amounted to approximately $770,400 during the first nine months of fiscal 2014, as compared to net cash provided by approximately $339,000 for the same period in fiscal 2013.

During the first nine months of fiscal 2014, we used cash of $813,000 for the repayment of short-term loan payable offset by cash received of $43,000 from related party advances.

Net cash provided by financing activities amounted to $339,000 during the first nine months of fiscal 2013 and primarily related to proceeds received of $351,900 from related party working capital advances offset by the repayment of related party advances of $12,500.

CASH ALLOCATION BY COUNTRIES

The functional currency of our Chinese subsidiaries is the Chinese RMB. Substantially all of our cash is held in the form of RMB at financial institutions located in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash accounts at financial institutions in the PRC are not insured. We have not experienced any losses in such accounts as of January 31, 2014.

- 24 -

In 1996, the Chinese government introduced regulations which relaxed restrictions on the conversion of the RMB; however restrictions still remain, including but not limited to restrictions on foreign invested entities. Foreign invested entities may only buy, sell or remit foreign currencies after providing valid commercial documents at only those banks authorized to conduct foreign exchanges. Furthermore, the conversion of RMB for capital account items, including direct investments and loans, is subject to PRC government approval. Chinese entities are required to establish and maintain separate foreign exchange accounts for capital account items. We cannot be certain Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the RMB, especially with respect to foreign exchange transactions. Accordingly, cash on deposit in banks in the PRC is not readily deployable by us for purposes outside of the PRC. Our cash position by geographic area is as follows:

	January 31, 2014		April 30, 2013
	(Unaudited)
China	$	825,525	$	516,071
United States		4,510		1,035
Total	$	830,035	$	517,106

Off Balance Sheet Arrangements

Under SEC regulations, we are required to disclose our off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, such as changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. An off-balance sheet arrangement means a transaction, agreement or contractual arrangement to which any entity that is not consolidated with us as a party, under which we have:

● Any obligation under certain guarantee contracts,

● Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets,

● Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to our stock and classified in stockholder’s equity in our statement of financial position, and

● Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.

We do not have any off-balance sheet arrangements that we are required to disclose pursuant to these regulations. In the ordinary course of business, we enter into operating lease commitments, purchase commitments and other contractual obligations. These transactions are recognized in our financial statements in accordance with U.S. GAAP.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with U.S. GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of our financial condition and results of operations, and which require us to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 1 to our consolidated financial statements. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.

- 25 -

Estimates

Significant estimates for the periods reported include the allowance for doubtful accounts which is based on an evaluation of our outstanding accounts receivable including the age of amounts due, the financial condition of our specific customers and historical bad debt experience. This evaluation methodology has proven to provide a reasonable estimate of bad debt expense in the past and we intend to continue to employ this approach in our analysis of collectability.  However, we are aware that given the current global economic crises, including that of the PRC, meaningful time horizons may change.  We intend to enhance our focus on the evaluation of our customers' sustainability and adjust our estimates as may be indicted.

We rely on assumptions such as volatility, forfeiture rate, and expected dividend yield when calculating the fair value of our derivative liability related to common stock purchase warrants. We also rely on assumptions and estimates to calculate our reserve for obsolete inventory and the depreciation of property, plant and equipment. We make assumptions of expiration of our products held as inventory based on historical experience and if applicable, regulatory recommendation. We also group property plant and equipment into similar groups of assets and estimate the useful life of each group of assets.

Further, we rely on certain assumptions and calculations underlying our provision for taxes in the PRC.  Assumptions and estimates employed in these areas are material to our reported financial conditions and results of operations.  These assumptions and estimates have been materially accurate in the past and are not expected to materially change in the future.  Actual results could differ from these estimates.

Revenue recognition

We follow the guidance of ASC 605, "Revenue Recognition,” and the Securities and Exchange Commission's Staff Accounting Bulletin (“SAB”) No. 104 and SAB Topic 13 for revenue recognition. In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

Long-lived assets

     We review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

 We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer,("CEO"), and our Chief Financial Officer("CFO"), to allow timely decisions regarding required disclosure.

Management, with the participation of our CEO and CFO, performed an evaluation of the effectiveness of our disclosure controls and procedures as of January 31, 2014.  

- 26 -

Based on this evaluation our management concluded that our disclosure controls and procedures were effective as of January 31, 2014 such that the information relating to our company, required to be disclosed in our Securities and Exchange Commission reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) is accumulated and communicated to our management, including our CEO, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation of our controls performed during the nine months ended January 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Risk factors describing the major risks to our business can be found under Item 1A, “Risk Factors”, in our fiscal 2013 Annual Report on Form 10-K. There has been no material change in our risk factors from those previously discussed in the fiscal 2013 Annual Report on Form 10-K.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.  MINE SAFETY DISCLOSURE.

None.

ITEM 5.  OTHER INFORMATION.

None 

ITEM 6.  EXHIBITS

Exhibit No.	Description of Exhibit
31.1	Section 302 Certificate of the Chief Executive Officer.*
31.2	Section 302 Certificate of Chief Financial Officer.*
32.1	Section 906 Certificate of Chief Executive Officer and Chief Financial Officer.*
101.INS	XBRL INSTANCE DOCUMENT**
101.SCH	XBRL TAXONOMY EXTENSION SCHEMA**
101.CAL	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE**
101.DEF	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE**
101.LAB	XBRL TAXONOMY EXTENSION LABEL LINKBASE**
101.PRE	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE**

* - Filed herewith.

** - In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.

- 27 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SUNWIN STEVIA INTERNATIONAL, INC.
Dated: March 24, 2014	By:	/s/ Dongdong Lin
		Dongdong Lin,
		Chief Executive Officer
Dated: March 24, 2014	By:	/s/ Fanjun Wu
		Fanjun Wu,
		Chief Financial Officer

- 28 -

EX-31.1

Exhibit 31.1

Rule 13a-14(a)/15d-14(a) Certification

I, Dongdong Lin, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended January 31, 2014 of Sunwin Stevia International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

March 24, 2014	/s/ Dongdong Lin
	Dongdong Lin,
	Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

Rule 13a-14(a)/15d-14(a) Certification

I, Fanjun Wu, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended January 31, 2014 of Sunwin Stevia International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

March 24, 2014	/s/ Fanjun Wu
	Fanjun Wu,
	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Section 1350 Certification

In connection with the quarterly report of Sunwin Stevia International, Inc. (the “Company”) on Form 10-Q for the period ended January 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Dongdong Lin, Chief Executive Officer of the Company, and I, Fanjun Wu, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

March 24, 2014	/s/ Dongdong Lin
	Dongdong Lin,
	Chief Executive Officer
March 24, 2014	/s/ Fanjun Wu
	Fanjun Wu,
	Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Note 4 - Inventories: Schedule of Inventory, Current (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Schedule of Inventory, Current

	January 31, 2014 (Unaudited)	April 30, 2013
Raw materials	$   1,149,987	$   1,099,001
Work in process	863,664	659,631
Finished goods	3,786,673	4,123,447
Inventories, gross	5,800,324	5,882,079
Less: reserve for obsolete inventory	(971,178)	(954,108)
Inventories, net	$   4,829,146	$   4,927,971

XML

Note 2- Summary of Significant Accounting Policies: Taxes Receivable (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Value Added Tax Receivable	$ 13,801	$ 0

XML

Note 16 - Concentrations and Credit Risk: Customer concentrations table (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Customer concentrations table

	Net Revenues
	For the nine months ended January 31, 2014		For the nine months ended January 31, 2013
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Qufu Shengwang Import and Export Trade Co., Ltd (1)	0	41.2%	0	46.0%
Guangdong Tengjun Veterinary Medicine Co., Ltd	0	0	11.6%	0
Total	0%	41.2%	11.6%	46.0%

XML

Note 13 - Stockholders' Equity (Details)	Jan. 31, 2014	Apr. 30, 2013
Details
Common stock authorized to issue	200,000,000
Shares, Outstanding	173,882,803	173,882,803

XML

Note 2- Summary of Significant Accounting Policies: Basic and Diluted Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Details
Income (Loss) Attributable to Parent	$ (166,062)	$ (826,841)	$ (1,709,446)	$ (3,064,956)
Weighted Average Number of Shares Issued, Basic	173,882,803	173,374,671	173,882,803	165,946,391
Weighted Average Number of Shares Outstanding, Diluted	173,882,803	173,374,671	173,882,803	165,946,391
Earnings Per Share, Basic	$ (0.001)	$ (0.005)	$ (0.009)	$ (0.018)
Earnings Per Share, Diluted	$ (0.001)	$ (0.005)	$ (0.009)	$ (0.018)

XML

Note 16 - Concentrations and Credit Risk: Vendor concentrations table (Details)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Details
Percent of purchase from Shandong Heze Zhongshun Pharmaceutical - Chinese Medicine	16.70%	38.10%
Percent of purchase from Qufu Longheng Materials - Chinese Medicine	18.70%	34.90%
Percent of purchase from Jiuquan Jiale Biotech Co., Ltd - Stevioside		20.00%
Percent of purchase from Gansu Fanzhi Biology Techonology Co.,Ltd - Chinese Medicine	17.20%
Percent of purchase from Qingdao Runhao Stevia Technology Co., Ltd - Stevioside		13.00%
Total percent of purchase from major suppliers - Chinese Medicine	52.60%	73.00%
Total percent of purchase from major suppliers - Stevioside	0.00%	33.00%

XML

Note 14 - Segment Information: Segment Information Table 2 (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Segment Information Table 2

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
(Loss) income before income taxes:
Chinese medicine	$             98,689	$      137,625	$             47,689	$         149,002
Stevioside	(238,493)	(806,192)	(1,705,763)	(1,495,243)
Corporate and other	(26,258)	(161,718) )	(51,198)	(1,718,715
Total consolidated (loss) income before income taxes	$       (166,062) )	$    (830,285)	$      (1,709,272)	$    (3,064,956)

XML

Note 2- Summary of Significant Accounting Policies: Basic and Diluted Earnings Per Share (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Basic and Diluted Earnings Per Share

BASIC AND DILUTED LOSS PER SHARE

Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations. The following table presents a reconciliation of basic and diluted net income per ordinary share:

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
Net Net loss allocable to common shareholders for basic and diluted net loss per common share	$          (166,062)	$         (826,841)	$      (1,709,446)	$      (3,064,956)
Weighted average common shares outstanding - basic	173,882,803	173,374,671	173,882,803	165,946,391
Effect of dilutive securities:
Warrants	0	0	0	0
Weighted average common shares outstanding – diluted	173,882,803	173,374,671	173,882,803	165,946,391
Net loss per common share - basic	$               (0.001)	$              (0.005)	$              (0.009)	$              (0.018)
Net loss per common share - diluted	$               (0.001)	$              (0.005)	$              (0.009)	$              (0.018)

For the three and nine months ended January 31, 2014 and 2013, the effect of 26,666,666 outstanding common stock purchase warrants were anti-dilutive as we reported a net loss applicable to our common shareholders for both periods., and these outstanding purchase warrants re anti-dilutive as the exercise price of the warrants exceeded the average market price.  As a result, basic loss per share was equal to diluted loss per share for the three and nine months ended January 31, 2014 and 2013.

XML

Note 16 - Concentrations and Credit Risk (Details) (USD $)	Jan. 31, 2014
Details
Deposits in PRC	$ 825,525

XML

Note 14 - Segment Information: Segment Information Table 1 (Details) (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Details
Revenue Chinese medicine - third party	$ 713,896	$ 1,111,530	$ 1,862,718	$ 2,475,830
Revenue Chinese medicine - related party	0	0	0	0
Revenue Chinese medicine	713,896	1,111,530	1,862,718	2,475,830
Revenue Stevioside - third party	1,680,795	687,414	4,338,845	3,615,509
Revenue Stevioside - related party	833,657	171,547	2,567,648	1,576,463
Revenue Stevioside	2,514,452	858,961	6,906,493	5,191,972
Total segment and consolidated revenues	3,228,348	1,970,491	8,769,211	7,667,802
Interest income (expense) Chinese medicine	92	1,667	370	1,733
Interest income (expense) Stevioside	(35,573)	(1,030)	(69,101)	4,719
Interest income (expense) Corporate and other	0	0	0	1,718
Total segment and consolidated interest income (expense)	(35,481)	637	(68,731)	8,170
Depreciation and amortization Chinese medicine	31,963	19,811	77,996	59,197
Depreciation and amortization Stevioside	432,169	532,909	1,311,822	1,358,451
Depreciation and amortization Corporate and other	81,294	0	243,881	0
Total segment and consolidated depreciation and amortization	$ 545,426	$ 552,720	$ 1,633,699	$ 1,417,648

XML

Note 2- Summary of Significant Accounting Policies: Concentrations of Credit Risk (Details) (USD $)	Jan. 31, 2014
Details
Cash and cash equivalents held in PRC	$ 825,525

XML

Note 15-commitments and Contingencies (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013	Dec. 08, 2011	Aug. 25, 2011
Details
Purchase price for apartment units held for sale				$ 2,390,325
Payment of purchase price for apartment units held for sale			1,195,162	717,097
Investment in real estate held for resale	$ 1,981,879	$ 1,947,042

XML

Note 16 - Concentrations and Credit Risk: Customer concentrations table (Details)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Details
Percent of sales to Qufu Shengwang Import and Export - Stevioside	41.20%	46.00%
Percent of sales to Guangdong Tengjun Veterinary Medicine Co., Ltd - Chinese Medicine		11.60%
Total percent of sales to major customers - Chinese Medicine	0.00%	11.60%
Total percent of sales to major customers - Stevioside	41.20%	46.00%

XML

Note 13 - Stockholders' Equity: Changes to Outstanding stock warrants table (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Warrants and Rights Outstanding	$ 26,666,666	$ 26,666,666
Stock Warrants Exercise Price	$ 0.35	$ 0.35

XML

Note 2- Summary of Significant Accounting Policies: Inventories (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Inventories

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method. An allowance is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected market value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the market value. These reserves are recorded based on estimates. At January 31, 2014 and April 30, 2013, the Company recorded a reserve for obsolete or slow-moving inventories of $971,178 and $954,108, respectively.

XML

Note 2- Summary of Significant Accounting Policies: Cash and Cash Equivalents (Details) (USD $)	Jan. 31, 2014
Details
Cash and cash equivalents held in PRC	$ 825,525
Cash and cash equivalents held in US	$ 4,510

XML

Note 7- Land Use Rights: Land use right table (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Land use right table

(Estimated Life)	January 31, 2014 (Unaudited)	April 30, 2013
Land use right (41-65 Years)	$   2,605,862	$   2,559,545
Less: accumulated amortization	(318,227)	(270,001)
Land use right, net	$   2,287,635	$   2,289,544

XML

Note 14 - Segment Information: Segment Information Table 3 (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Segment tangible assets Chinese medicine	$ 648,711	$ 644,073
Segment tangible assets Stevioside	14,287,922	15,081,311
Segment tangible assets Corporate and other	0	0
Total consolidated assets	$ 14,936,633	$ 15,725,384

XML

Note 2- Summary of Significant Accounting Policies: Research and Development (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Research and Development

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying consolidated statements of operations. Research and development costs are incurred on a project specific basis. Research and development costs were $24,343 and $64,541 for the nine months ended January 31, 2014 and 2013, respectively.

XML

Note 2- Summary of Significant Accounting Policies: Inventories (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Reserve for obsolete or slow-moving inventories	$ 971,178	$ 954,108

XML

Note 9 - Related Party Transactions (Details) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Apr. 30, 2013
Details
Accounts receivable - related party	$ 644,448		$ 1,239,222
Revenue from Related Parties	2,567,648	1,576,463
Due to Pharmaceutical Corporation for Working Capital	220,883		110,018
Total Due To Related Parties	220,883		174,404
Due from Qufu Shengwang	$ 0

XML

Note 5 - Property and Equipment: Property and equipment table (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Furniture and Fixtures, Gross	$ 55,282	$ 48,741
Auto and Trucks	936,520	907,480
Machinery and Equipment, Gross	12,083,165	11,687,057
Buildings and Improvements, Gross	10,401,306	10,192,769
Construction in Progress, Gross	734,772	668,330
Property, Plant and Equipment, Gross	24,211,045	23,504,377
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(9,274,412)	(7,778,993)
Property and equipment, net	$ 14,936,633	$ 15,725,384

XML

Note 14 - Segment Information: Segment Information Table 3 (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Segment Information Table 3

	January 31, 2014	April 30, 2013
Segment tangible assets:
Chinese medicine	$       648,711	$       644,073
Stevioside	14,287,922	15,081,311
Corporate and other	0	0
Total consolidated assets	$  14,936,633	$ 15,725,384

XML

Note 5 - Property and Equipment

9 Months Ended

Jan. 31, 2014

Notes

Note 5 - Property and Equipment

NOTE 5 - PROPERTY AND EQUIPMENT

At January 31, 2014 and April 30, 2013, property and equipment consisted of the following:

(Estimated Life)	January 31, 2014 (Unaudited)	April 30, 2013
Office Equipment (5-7 Years)	$          55,282	$          48,741
Auto and Trucks (10 Years)	936,520	907,480
Manufacturing Equipment (20 Years)	12,083,165	11,687,057
Buildings (20 Years)	10,401,306	10,192,769
Construction in Process	734,772	668,330
Property and Equipment, gross	24,211,045	23,504,377
Less: Accumulated Depreciation	(9,274,412)	(7,778,993)
Property and equipment, net	$  14,936,633	$  15,725,384

For the nine months ended January 31, 2014 and 2013, depreciation expense totaled $1,346,728 and $1,240,136, respectively. Depreciation is not taken during the period of construction or equipment installation. Upon completion of the installation of manufacturing equipment or any construction in progress, construction in progress balances will be classified to their respective property and equipment category.

XML

Note 5 - Property and Equipment (Details) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Details
Depreciation expense	$ 1,346,728	$ 1,240,136

XML

Note 13 - Stockholders' Equity: Changes to Outstanding stock warrants table (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Changes to Outstanding stock warrants table

	Shares	Weighted Average  Exercise Price
Outstanding at April 30, 2013	26,666,666	$             0.35
Granted	0	0
Exercised	0	0
Forfeited	0	0
Warrants exercisable at January 31, 2014 (unaudited)	26,666,666	$   0.35

XML

Note 2- Summary of Significant Accounting Policies: Taxes Receivable (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Taxes Receivable

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at January 31, 2014 and April 30, 2013 amounted to $13,801 and $0, respectively, consisting primarily of VAT taxes payable.

XML

Note 2- Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Fair Value of Financial Instruments

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC 820-10-35-37 to measure the fair value of our financial instruments. ASC 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.

XML

Note 2- Summary of Significant Accounting Policies: Foreign Currency Translation (Details)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Apr. 30, 2013
Details
Foreign Currency Exchange Rate, Translation	6.10		6.21
Average exchange rates	6.15	6.30

XML

Note 13 - Stockholders' Equity: Outstanding stock warrants table (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Outstanding stock warrants table

	Warrants Outstanding			Warrants Exercisable
Exercise Prices	Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
$                 0.35	26,666,666	0.01	$   0.35	26,666,666	]
	26,666,666		$                0.35	26,666,666	$                0.35

XML

Note 2- Summary of Significant Accounting Policies: Revenue Recognition (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Revenue Recognition

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

XML

Note 2- Summary of Significant Accounting Policies: Grant Income (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Grant Income

GRANT INCOME

Grants received from PRC government agencies are recognized as deferred grant income and recognized in the consolidated statements of operations as and when they are incurred for the specific research and development projects or general operation purpose for which these grants are received.

XML

Note 4 - Inventories

9 Months Ended

Jan. 31, 2014

Notes

Note 4 - Inventories

NOTE 4 - INVENTORIES

At January 31, 2014 and April 30, 2013, inventories consisted of the following:

	January 31, 2014 (Unaudited)	April 30, 2013
Raw materials	$   1,149,987	$   1,099,001
Work in process	863,664	659,631
Finished goods	3,786,673	4,123,447
Inventories, gross	5,800,324	5,882,079
Less: reserve for obsolete inventory	(971,178)	(954,108)
Inventories, net	$   4,829,146	$   4,927,971

XML

Note 2- Summary of Significant Accounting Policies: Income Taxes (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Income Taxes

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns.

We apply the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our consolidated financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of January 31, 2014, the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

XML

Note 5 - Property and Equipment: Property and equipment table (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Property and equipment table

(Estimated Life)	January 31, 2014 (Unaudited)	April 30, 2013
Office Equipment (5-7 Years)	$          55,282	$          48,741
Auto and Trucks (10 Years)	936,520	907,480
Manufacturing Equipment (20 Years)	12,083,165	11,687,057
Buildings (20 Years)	10,401,306	10,192,769
Construction in Process	734,772	668,330
Property and Equipment, gross	24,211,045	23,504,377
Less: Accumulated Depreciation	(9,274,412)	(7,778,993)
Property and equipment, net	$  14,936,633	$  15,725,384

XML

Note 2- Summary of Significant Accounting Policies: Long-lived Assets (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses	$ 209,194	$ 209,194

XML

Note 13 - Stockholders' Equity: Outstanding stock warrants table (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Stock Warrants Exercise Price	$ 0.35	$ 0.35
Warrants and Rights Outstanding	$ 26,666,666	$ 26,666,666
Weighted Average Remaining Contractual Life	0.01
Stock Warrants Weighted Average Exercise Price	$ 0.35
Warrants Exercisable	26,666,666

XML

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jan. 31, 2014	Apr. 30, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 830,035	$ 517,106
Accounts receivable, net of allowance for doubtful accounts of $1,134,102 and $1,000,291, respectively	1,397,527	1,614,152
Accounts receivable - related party	644,448	1,239,222
Notes receivable		41,851
Loan receivable		43,614
Inventories, net	4,829,146	4,927,971
Prepaid expenses and other current assets	1,300,365	1,189,416
Total Current Assets	9,001,521	9,573,332
Investment in real estate held for resale	1,981,879	1,947,042
Property and equipment, net	14,936,633	15,725,384
Intangible assets, net	1,165,209	1,409,090
Land use rights, net	2,287,635	2,289,544
Total Assets	29,372,877	30,944,392
CURRENT LIABILITIES:
Accounts payable and accrued expenses	3,310,019	3,626,117
Loan payable		804,829
Deferred grant income	764,614
Due to related party	220,883	174,404
Total Current Liabilities	4,295,516	4,605,350
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value, 200,000,000 shares authorized; 173,882,803 and 173,882,803 shares issued and outstanding as of January 31, 2013 and April 30, 2013, respectively	173,883	173,883
Additional paid-in capital	33,479,529	33,479,529
Accumulated deficit	(14,539,152)	(12,829,706)
Accumulated other comprehensive income	5,963,101	5,515,336
Total Stockholders' Equity	25,077,361	26,339,042
Total Liabilities and Stockholders' Equity	$ 29,372,877	$ 30,944,392

XML

Note 14 - Segment Information: Segment Information Table 1 (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Segment Information Table 1

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
Revenues:
Chinese medicine – third party	$           713,896	$       1,111,530	$       1,862,718	$   2,475,830
Chinese medicine – related party	0	0	0	0
Total Chinese medicine	713,896	1,111,530	1,862,718	2,475,830
Stevioside – third party	1,680,795	687,414	4,338,845	3,615,509
Stevioside – related party	833,657	171,547	2,567,648	1,576,463
Total Stevioside	2,514,452	858,961	6,906,493	5,191,972
Total segment and consolidated revenues	$       3,228,348	$       1,970,491	$       8,769,211	$   7,667,802
Interest income (expense):
Chinese medicine	$                     92	$               1,667	$                   370	$           1,733
Stevioside	(35,573)	(1,030)	(69,101)	4,719
Corporate and other	0	0	0	1,718
Total segment and consolidated interest income (expense)	$           (35,481)	$                  637	$           (68,731)	$           8,170
Depreciation and amortization:
Chinese medicine	$             31,963	$             19,811	$             77,996	$         59,197
Stevioside	432,169	532,909	1,311,822	1,358,451
Corporate and other	81,294	0	243,881	0
Total segment and consolidated depreciation and amortization	$          545,426	$          552,720	$       1,633,699	$   1,417,648

XML

Note 2- Summary of Significant Accounting Policies

9 Months Ended

Jan. 31, 2014

Notes

Note 2- Summary of Significant Accounting Policies

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. The accompanying unaudited condensed consolidated financial statements for the interim periods presented are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented. Certain financial statement amounts relating to prior periods have been reclassified to conform to the current period presentation.

These unaudited condensed consolidated interim financial statements should be read in conjunction with the financial statements and footnotes for the year ended April 30, 2013 included in our Form 10-K as filed with the SEC. The results of operations and cash flows for the nine months ended January 31, 2014 are not necessarily indicative of the results of operations or cash flows which may be reported for future periods or the full fiscal year.

Our unaudited condensed consolidated financial statements include the accounts of Sunwin and all our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Our subsidiaries include the following:

    - Qufu Natural Green;

    - Qufu Shengren;

    - Qufu Shengwang;

    - Sunwin Tech; and

    - Sunwin USA

As reflected in the accompanying unaudited condensed consolidated financial statements, during the first nine months of fiscal year 2014, the Company had a net loss of approximately $1.7 million and net cash provided by operations of $1.3 million. At January 31, 2014, we had working capital of $4.7million, including cash of $830,000. We believe the Company has the ability to further implement its business plan, raise additional capital, generate more revenues, and collect receivables from the third party and related parties to increase the working capital.

USE OF ESTIMATES

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates include the allowance for doubtful accounts, the allowance for obsolete inventory, the useful life of property and equipment and intangible assets, assumptions used in assessing impairment of long-term assets and valuation of deferred tax assets, and the value of stock-based compensation.  Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of January 31, 2014, we held $825,525 of our cash and cash equivalents with commercial banking institutions in the PRC, and $4,510 with banks in the United States. As of April 30, 2013, we held $516,071 of our cash and cash equivalents with commercial banking institution in PRC, and $1,035 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through January 31, 2014.

ACCOUNTS RECEIVABLE

Accounts receivable and other receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At January 31, 2014 and April 30, 2013, the allowance for doubtful accounts was $1,134,102 and $1,000,291, respectively.

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method. An allowance is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected market value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the market value. These reserves are recorded based on estimates. At January 31, 2014 and April 30, 2013, the Company recorded a reserve for obsolete or slow-moving inventories of $971,178 and $954,108, respectively.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

LONG-LIVED ASSETS

In accordance with ASC Topic 360, we review and evaluate our long-lived assets, including property and equipment, intangible assets, and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates. Based on our evaluation, for the three and nine month ended January 31, 2013, we recorded an impairment loss of $209,194 and $209,194, related to impairment of the carrying amounts certain machinery and equipment deemed unusable as, respectively.

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC 820-10-35-37 to measure the fair value of our financial instruments. ASC 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at January 31, 2014 and April 30, 2013 amounted to $13,801 and $0, respectively, consisting primarily of VAT taxes payable.

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

GRANT INCOME

Grants received from PRC government agencies are recognized as deferred grant income and recognized in the consolidated statements of operations as and when they are incurred for the specific research and development projects or general operation purpose for which these grants are received.

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns.

We apply the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our consolidated financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of January 31, 2014, the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

BASIC AND DILUTED LOSS PER SHARE

Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations. The following table presents a reconciliation of basic and diluted net income per ordinary share:

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
Net Net loss allocable to common shareholders for basic and diluted net loss per common share	$          (166,062)	$         (826,841)	$      (1,709,446)	$      (3,064,956)
Weighted average common shares outstanding - basic	173,882,803	173,374,671	173,882,803	165,946,391
Effect of dilutive securities:
Warrants	0	0	0	0
Weighted average common shares outstanding – diluted	173,882,803	173,374,671	173,882,803	165,946,391
Net loss per common share - basic	$               (0.001)	$              (0.005)	$              (0.009)	$              (0.018)
Net loss per common share - diluted	$               (0.001)	$              (0.005)	$              (0.009)	$              (0.018)

For the three and nine months ended January 31, 2014 and 2013, the effect of 26,666,666 outstanding common stock purchase warrants were anti-dilutive as we reported a net loss applicable to our common shareholders for both periods., and these outstanding purchase warrants re anti-dilutive as the exercise price of the warrants exceeded the average market price.  As a result, basic loss per share was equal to diluted loss per share for the three and nine months ended January 31, 2014 and 2013.

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company is the U.S. dollar and the functional currency of the Company’s operating subsidiaries is the Chinese Renminbi (“RMB”).  In accordance with ASC 830-20-35, the consolidated financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements and cash flows. Equity accounts were stated at their historical rate. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2013	RMB 6.21 to $1.00
As of January 31, 2014	RMB 6.10 to $1.00
Nine months ended January 31, 2014	RMB 6.15 to $1.00
Nine months ended January 31, 2013	RMB 6.30 to $1.00

CONCENTRATIONS OF CREDIT RISK

Substantially all of our operations are carried out in the PRC. Accordingly, our business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC’s economy. Our operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. Our results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At January 31, 2014, we had $825,525 on deposit in China, which is not insured. We have not experienced any losses in such accounts through January 31, 2014.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

STOCK-BASED COMPENSATION

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of ASC Topic 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). “FASB” ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company records compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated, based on the then current fair value, at each subsequent reporting date.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying consolidated statements of operations. Research and development costs are incurred on a project specific basis. Research and development costs were $24,343 and $64,541 for the nine months ended January 31, 2014 and 2013, respectively.

RECENT ACCOUNTING PRONOUNCEMENTS

In March 2013, the FASB issued ASU 2013-05 “Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity.” ASU 2013-05 addresses the accounting for the cumulative translation adjustment when a parent either sells part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. For public entities, the ASU is effective prospectively for fiscal years, and interim periods, within those years, beginning after December 15, 2013. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on the Company’s consolidated financial statements.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

XML

Note 3 -investment in Real Estate Held For Resale (Details) (USD $)	Apr. 30, 2013	Dec. 08, 2011	Aug. 25, 2011
Details
Purchase price for apartment units held for sale			$ 2,390,325
Payment of purchase price for apartment units held for sale		1,195,162	717,097
Investment in real estate held for resale	$ 1,947,042

XML

Note 2- Summary of Significant Accounting Policies: Concentrations of Credit Risk (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Concentrations of Credit Risk

CONCENTRATIONS OF CREDIT RISK

Substantially all of our operations are carried out in the PRC. Accordingly, our business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC’s economy. Our operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. Our results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At January 31, 2014, we had $825,525 on deposit in China, which is not insured. We have not experienced any losses in such accounts through January 31, 2014.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

XML

Note 7- Land Use Rights: Land use right table (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Land use right, gross	$ 2,605,862	$ 2,559,545
Accumulated amortization of Land Use Rights	(318,227)	(270,001)
LandUseRight	$ 2,287,635	$ 2,289,544

XML

Note 2- Summary of Significant Accounting Policies: Use of Estimates (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Use of Estimates

USE OF ESTIMATES

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates include the allowance for doubtful accounts, the allowance for obsolete inventory, the useful life of property and equipment and intangible assets, assumptions used in assessing impairment of long-term assets and valuation of deferred tax assets, and the value of stock-based compensation.  Actual results could differ from those estimates.

XML

Note 2- Summary of Significant Accounting Policies: Stock Based Compensation (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Stock Based Compensation

STOCK-BASED COMPENSATION

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of ASC Topic 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). “FASB” ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company records compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated, based on the then current fair value, at each subsequent reporting date.

XML

Note 2- Summary of Significant Accounting Policies: Accounts Receivable (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Accounts Receivable

ACCOUNTS RECEIVABLE

Accounts receivable and other receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At January 31, 2014 and April 30, 2013, the allowance for doubtful accounts was $1,134,102 and $1,000,291, respectively.

XML

Note 10 - Prepaid Expenses and Other Current Assets (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Prepaid expenses and other current assets	$ 1,300,365	$ 1,189,416
Prepayments to suppliers	929,656	718,437
Employee advances and others	178,274	159,149
Deposits for Land Use Right	192,435	216,417
Prepaid VAT		$ 95,413

XML

Note 3 -investment in Real Estate Held For Resale

9 Months Ended

Jan. 31, 2014

Notes

Note 3 -investment in Real Estate Held For Resale

NOTE 3 - INVESTMENT IN REAL ESTATE HELD FOR RESALE

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units were expected to be delivered by December 30, 2012. As of January 31, 2014, we are processing the deed and other legal documents for the apartment; the apartment units are expected to be delivered by the fourth quarter of fiscal year 2014. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance of approximately $478,066 due upon completion of the ownership documents and transfer of the apartment units to us. As of January 31, 2014 and April 30, 2013, we classified investment in real estate held for resale as a long-term asset since we do not plan on selling the apartment units within one year. As of January 31, 2014 and April 30, 2013, investment in real estate held for resale amounted to 3XJJTZZL|Tag=us-gaap:RealEstateInvestments|Label=Investment in real estate held for resale|Time=2014-01-31»$1,981,879 and $1,947,042, respectively.

XML

"SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Revenues:
Revenues	$ 2,394,691	$ 1,798,944	$ 6,201,563	$ 6,091,339
Revenues - related party	833,657	171,547	2,567,648	1,576,463
Total revenues	3,228,348	1,970,491	8,769,211	7,667,802
Cost of revenues	2,549,994	1,572,761	7,344,223	6,212,586
Gross profit	678,354	397,730	1,424,988	1,455,216
Operating expenses:
Loss on disposition of property and equipment		209,194		209,194
Selling expenses	361,417	261,452	930,684	751,873
General and administrative expenses	818,861	737,802	2,621,703	3,551,722
Total operating expenses	1,180,278	1,208,448	3,552,387	4,512,789
Loss from operations	(501,924)	(810,718)	(2,127,399)	(3,057,573)
Other income (expense):
Other income (expenses)	371,343	(20,204)	486,858	(15,553)
Interest (expenses) income	(35,481)	637	(68,731)	8,170
Total other income	335,862	(19,567)	418,217	(7,383)
Loss before income taxes	(166,062)	(830,285)	(1,709,446)	(3,064,956)
Income taxes expense		3,444	(174)
Net loss	(166,062)	(826,841)	(1,709,446)	(3,064,956)
Comprehensive loss
Net loss	(166,062)	(826,841)	(1,709,446)	(3,064,956)
Foreign currency translation adjustment	30,286	11,377	447,765	74,779
Total Comprehensive loss	$ (135,776)	$ (815,464)	$ (1,261,681)	$ (2,990,177)
Net Loss per share-basic and diluted	$ (0.001)	$ (0.005)	$ (0.010)	$ (0.018)
Weighted average common shares outstanding - basic and diluted	173,882,803	173,347,671	173,882,803	165,946,391

XML

Note 13 - Stockholders' Equity

9 Months Ended

Jan. 31, 2014

Notes

Note 13 - Stockholders' Equity

NOTE 13 - STOCKHOLDERS' EQUITY

Common stock

At January 31, 2014, we are authorized to issue 200,000,000 shares of common stock. We had 173,882,803 and 173,882,803  shares outstanding at January 31, 2014 and April 30, 2013, respectively.

Common stock purchase warrants

A summary of the changes to our outstanding stock warrants during the nine months ended January 31, 2014 is as follows:

	Shares	Weighted Average  Exercise Price
Outstanding at April 30, 2013	26,666,666	$             0.35
Granted	0	0
Exercised	0	0
Forfeited	0	0
Warrants exercisable at January 31, 2014 (unaudited)	26,666,666	$   0.35

Common stock purchase warrants (continued)

The following information applies to all warrants outstanding at January 31, 2014:

	Warrants Outstanding			Warrants Exercisable
Exercise Prices	Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
$                 0.35	26,666,666	0.01	$   0.35	26,666,666	]
	26,666,666		$                0.35	26,666,666	$                0.35

XML

Document and Entity Information (USD $)	9 Months Ended
	Jan. 31, 2014	Mar. 16, 2014	Oct. 31, 2012
Document and Entity Information:
Entity Registrant Name	SUNWIN STEVIA INTERNATIONAL, INC.
Document Type	10-Q
Document Period End Date	Jan. 31, 2014
Amendment Flag	false
Entity Central Index Key	0000806592
Current Fiscal Year End Date	--04-30
Entity Common Stock, Shares Outstanding		173,882,803
Entity Public Float			$ 24,365,308
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

XML

Note 14 - Segment Information

9 Months Ended

Jan. 31, 2014

Notes

Note 14 - Segment Information

NOTE 14 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three and nine months ended January 31, 2014 and 2013; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2014 and 2013 is as follows:

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
Revenues:
Chinese medicine – third party	$           713,896	$       1,111,530	$       1,862,718	$   2,475,830
Chinese medicine – related party	0	0	0	0
Total Chinese medicine	713,896	1,111,530	1,862,718	2,475,830
Stevioside – third party	1,680,795	687,414	4,338,845	3,615,509
Stevioside – related party	833,657	171,547	2,567,648	1,576,463
Total Stevioside	2,514,452	858,961	6,906,493	5,191,972
Total segment and consolidated revenues	$       3,228,348	$       1,970,491	$       8,769,211	$   7,667,802
Interest income (expense):
Chinese medicine	$                     92	$               1,667	$                   370	$           1,733
Stevioside	(35,573)	(1,030)	(69,101)	4,719
Corporate and other	0	0	0	1,718
Total segment and consolidated interest income (expense)	$           (35,481)	$                  637	$           (68,731)	$           8,170
Depreciation and amortization:
Chinese medicine	$             31,963	$             19,811	$             77,996	$         59,197
Stevioside	432,169	532,909	1,311,822	1,358,451
Corporate and other	81,294	0	243,881	0
Total segment and consolidated depreciation and amortization	$          545,426	$          552,720	$       1,633,699	$   1,417,648

	Three Months Ended January 31,		Nine Months Ended January 31,
	2014	2013	2014	2013
(Loss) income before income taxes:
Chinese medicine	$             98,689	$      137,625	$             47,689	$         149,002
Stevioside	(238,493)	(806,192)	(1,705,763)	(1,495,243)
Corporate and other	(26,258)	(161,718) )	(51,198)	(1,718,715
Total consolidated (loss) income before income taxes	$       (166,062) )	$    (830,285)	$      (1,709,272)	$    (3,064,956)

	January 31, 2014	April 30, 2013
Segment tangible assets:
Chinese medicine	$       648,711	$       644,073
Stevioside	14,287,922	15,081,311
Corporate and other	0	0
Total consolidated assets	$  14,936,633	$ 15,725,384

XML

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,709,446)	$ (3,064,956)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation expense	1,346,728	1,240,136
Amortization of intangible assets	243,881	135,490
Amortization of land use right	43,090	42,022
Realized comprehensive loss	1,535
Loss on disposition of property and equipment		209,194
Stock issued for employee compensation		810,000
Stock issued for services		614,959
Inventory impairment change		(3,593)
Allowance for doubtful accounts	115,101	(91,648)
Changes in operating assets and liabilities:
Accounts receivable and notes receivable	170,984	982,660
Accounts receivable - related party	612,620	(175,178)
Inventories	185,685	(968,145)
Prepaid expenses and other current assets	(185,478)	(937,729)
Due from related party		(792,126)
Tax receivable		(135,966)
Accounts payable and accrued expenses	(391,893)	(263,390)
Deferred grant income	759,252
Taxes payable	110,144	(73,310)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	1,302,203	(2,471,580)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(273,794)	(2,677,493)
Increase in loan receivable		(1,718)
Proceeds from loan receivable	43,614	1,921,358
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(230,180)	(757,853)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of short-term loan	(813,484)
Advance due to related party		351,873
Proceed from (repayment of) related party advances	43,052	(12,546)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(770,432)	339,327
EFFECT OF EXCHANGE RATE ON CASH	12,894	(495)
NET CHANGE IN CASH	312,929	(2,890,601)
Cash	517,106	2,958,895
Cash	830,035	68,294
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes	174	35,092
NON-CASH INVESTING AND FINANCING ACTIVITIES
Intangible assets acquired from acquistion		$ 1,625,874
Shares issued for acquisition		1,625,874

XML

Note 8 - Loan Receivable

9 Months Ended

Jan. 31, 2014

Notes

Note 8 - Loan Receivable

NOTE 8 - LOAN RECEIVABLE

On December 22, 2010, we loaned $500,000 to CDI China, Inc., a subsidiary of CD International Enterprises, Inc., and an affiliate of CDI our corporate management services provider. The loan bears interest at the rate of 3% per annum and the principal balance and accrued interest were due March 30, 2011. Principal balance of $305,459 was repaid and part of accrued interest of $171,720 was repaid to us by CDI China, Inc. during fiscal 2012 and 2013. As of January 31, 2014, CDI China, Inc. repaid all remaining principal balances and accrued interest.

XML

Note 7- Land Use Rights

9 Months Ended

Jan. 31, 2014

Notes

Note 7- Land Use Rights

NOTE 7 - LAND USE RIGHTS

Land use right consisted of the following:

(Estimated Life)	January 31, 2014 (Unaudited)	April 30, 2013
Land use right (41-65 Years)	$   2,605,862	$   2,559,545
Less: accumulated amortization	(318,227)	(270,001)
Land use right, net	$   2,287,635	$   2,289,544

 In conjunction with our acquisition of Qufu Shengwang, we acquired land use rights for properties located in the PRC until March 14, 2054. For the nine month ended January 31, 2014 and 2013, amortization expense amounted to $43,090 and $42,022, respectively.

XML

Note 2- Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Cash and Cash Equivalents

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of January 31, 2014, we held $825,525 of our cash and cash equivalents with commercial banking institutions in the PRC, and $4,510 with banks in the United States. As of April 30, 2013, we held $516,071 of our cash and cash equivalents with commercial banking institution in PRC, and $1,035 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through January 31, 2014.

XML

Note 15-commitments and Contingencies

9 Months Ended

Jan. 31, 2014

Notes

Note 15-commitments and Contingencies

NOTE 15 - COMMITMENTS AND CONTINGENCIES

We lease office and manufacturing space under leases in Shandong, China that expire through 2014.

All facilities related to traditional Chinese medicine segment are leased from Pharmaceutical Corporation, a related party. The term of this lease expired in October, 2012 and provides for annual lease payments of $23,400. We paid the rent for this facility in fiscal 2012 which was included in the management fee we paid to Pharmaceutical Corporation during fiscal 2012. After October 1, 2012 Pharmaceutical Corporation agreed to waive the lease payments.

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units were expected to be delivered by December 30, 2012. As of April 30, 2014, we did not receive the deed and other legal documents for the apartment because the local government did not finish inspection; the company does not know when the apartment units can be delivered. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066 due upon completion of the ownership documents and transfer of the apartment units to us. As January 31, 2014 and April 30, 2013, we classified investment in real estate held for resale as a long-term asset since we do not plan on selling the apartment units within one year. As of January 31, 2014 and April 30, 2013, investment in real estate held for resale amounted to $1,981,879 and $1,947,042, respectively.

XML

Note 11 - Grant Income

9 Months Ended

Jan. 31, 2014

Notes

Note 11 - Grant Income

 NOTE 11 – GRANT INCOME

Deferred grant income at January 31, 2014 and April 30, 2013 totaled $764,614 and $0, respectively. On January 26, 2014, we received grant funding of $1,146,921 (RMB 7,000,000), in exchange for commitments made by us to the local government of Qufu city to provide research and development for the planting of stevia plants, for the development of biological methods to improve lower-grade stevia product to higher grade stevia, and applying biological method to change the taste of stevia to meet market demand. The grant term is for three years, from January 1, 2013 through December 2015. Deferred grant income is being amortized as an increase to other income and amortized over a 3-year period by straight line method from January of 2013.

XML

Note 4 - Inventories: Schedule of Inventory, Current (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Inventory, Raw Materials, Gross	$ 1,149,987	$ 1,099,001
Inventory, Work in Process, Gross	863,664	659,631
Inventory, Finished Goods, Gross	3,786,673	4,123,447
Inventory, Gross	5,800,324	5,882,079
Reserve for obsolete inventory	(971,178)	(954,108)
Inventories, net	$ 4,829,146	$ 4,927,971

XML

Note 9 - Related Party Transactions

9 Months Ended

Jan. 31, 2014

Notes

Note 9 - Related Party Transactions

NOTE 9 - RELATED PARTY TRANSACTIONS

Accounts receivable – related party

At January 31, 2014 and April 30, 2013, we reported $644,448 and $1,239,222 in accounts receivable – related party, respectively.  Accounts receivable – related party reflected amounts due from Qufu Shengwang Import and Export Corporation, a Chinese entity owned by our Chairman, Mr. Laiwang Zhang, for merchandise that has been delivered. For the three months ended January 31, 2014 and 2013, related party revenues were $833,657and $171,547, respectively. For the nine months ended January 31, 2014 and 2013, related party revenues were $2,567,648 and $1,576,463, respectively.

Due to (from) related parties

From time to time, we received advances from related parties and advanced funds to related parties for working capital purposes. The advances bear no interest and are payable on demand.  For the nine months ended January 31, 2014, due to (from) related party activities consisted of the following: 

	Pharmaceutical Corporation	Qufu Shengwang Import and Export	Total
Balance due to related parties, April 30, 2013	$     110,018	«3ZJJUFA0|Tag=fil:DueToQufuShengwang|Type=credit|Period=instant|Label=Due to Qufu Shengwang|Time=2013-04-30»$        64,386	$     174,404
Working capital advances from related parties	305,509	249,220	554,729
Repayments	(195,624)	(313,606)	(509,230)
Effect of foreign currency exchange	980	0	980
Balance due from related parties, January 31, 2014	$     220,883	$ 0	$     220,883

XML

Note 10 - Prepaid Expenses and Other Current Assets

9 Months Ended

Jan. 31, 2014

Notes

Note 10 - Prepaid Expenses and Other Current Assets

NOTE 10 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets at January 31, 2014 and April 30, 2013 totaled $1,300,365 and $1,189,416, respectively. As of January 31, 2014, prepaid expenses and other current assets includes $929,656 of prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us; $178,274 for employee advances and a $192,435 deposit for renewing land use rights. During the third quarter of fiscal 2013, Qufu Shengwang paid Qufu Public Auction Center $608,920 as deposit for renewing the land use right. The deposit is required for the Center to do the appraisal of the land use right. In the fourth quarter of fiscal 2013 and in the third quarter of fiscal 2014, we received a refund of this deposit of $388,631 and $27,854, respectively.

As of April 30, 2013, prepaid expenses and other current assets includes $718,437 of prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us; $159,149 for employee advances; $95,413 of prepaid VAT and a $216,417 in a deposit for renewing land use rights.

XML

Note 12- Loan Payable

9 Months Ended

Jan. 31, 2014

Notes

Note 12- Loan Payable

NOTE 12 - LOAN PAYABLE

In March 18, 2013, we entered to a loan agreement for approximately $809,822 (RMB 5,000,000) with China Construction Bank. According to the terms of the agreement with China Construction Bank, the loan bears interest at the rate of 7.8% per annum and the principal balance with accrued interest was due on March 17, 2014. We repaid the principal amounts of the loan with all accrued interest in January 2014.  At January 31, 2014 and April 30, 2013, loans payable amounted to $0 and $804,829, respectively.

XML

Note 6 - Intangible Assets: Schedule of Intangible Assets and Goodwill (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Only Sweet name rights and related technologies	$ 587,183	$ 587,183
Distribution agreement and related distribution channels	1,038,691	1,038,691
Finite-Lived Intangible Assets, Gross	1,625,874	1,625,874
Accumulated amortization of Intangible Assets	(460,665)	(216,784)
Intangible Assets, Current	$ 1,165,209	$ 1,409,090

XML

Note 8 - Loan Receivable (Details) (USD $)	Dec. 22, 2010
Details
Loan Receivable from CDI China	$ 500,000

XML

Note 6 - Intangible Assets (Details) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Aug. 22, 2012
Details
Share issued for acquisition			7,666,666
Value of Shares issued for Acquisition			$ 1,533,333
Cash paid for acquisition			92,541
Amortization of Acquired Intangible Assets	$ 243,881	$ 135,490

XML

Note 2- Summary of Significant Accounting Policies: Foreign Currency Translation (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Foreign Currency Translation

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company is the U.S. dollar and the functional currency of the Company’s operating subsidiaries is the Chinese Renminbi (“RMB”).  In accordance with ASC 830-20-35, the consolidated financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements and cash flows. Equity accounts were stated at their historical rate. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2013	RMB 6.21 to $1.00
As of January 31, 2014	RMB 6.10 to $1.00
Nine months ended January 31, 2014	RMB 6.15 to $1.00
Nine months ended January 31, 2013	RMB 6.30 to $1.00

XML

Note 2- Summary of Significant Accounting Policies: Accounts Receivable (Details) (USD $)	Jan. 31, 2014	Apr. 30, 2013
Details
Allowance for doubtful accounts	$ 1,134,102	$ 1,000,291

XML

Note 17 - Subsequent Events

9 Months Ended

Jan. 31, 2014

Notes

Note 17 - Subsequent Events

NOTE 17 - SUBSEQUENT EVENTS

The Company has evaluated subsequent events from January 31, 2014 through the date whereupon the financial statements were issued and has determined that there are no items to disclose.

XML

Note 2- Summary of Significant Accounting Policies: Property and Equipment (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

XML

Note 16 - Concentrations and Credit Risk: Vendor concentrations table (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Vendor concentrations table

	Net Purchases
	For the nine months ended January 31, 2014		For the nine months ended January 31, 2013
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd	16.7%	0	38.1%	0
Qufu Longheng Materials Co., Ltd	18.7%	0	34.9%	0
Jiuquan Jiale Biotech Co., Ltd	0	0	0	20.0%
Gansu Fanzhi Biology Technology Co.,Ltd	17.2%	0	0	0
Qingdao Runhao Stevia Technology Co., Ltd	0	0	0	13.0%
Total	52.6%	0%	73.0%	33.0%

XML

Note 6 - Intangible Assets: Schedule of Intangible Assets and Goodwill (Tables)

9 Months Ended

Jan. 31, 2014

Tables/Schedules

Schedule of Intangible Assets and Goodwill

(Estimated Life)	January 31, 2014 (Unaudited)	April 30, 2013
Only Sweet name rights and related technologies (5 Years)	$      587,183	$      587,183
Distribution agreement and related distribution channels (5 Years)	1,038,691	1,038,691
Intangible assets, gross	1,625,874	1,625,874
Less: accumulated amortization	(460,665)	(216,784)
Intangible Assets, net	$   1,165,209	$   1,409,090

XML

Note 1 - Organization and Operations

9 Months Ended

Jan. 31, 2014

Notes

Note 1 - Organization and Operations

NOTE 1 - ORGANIZATION AND OPERATIONS

DESCRIPTION OF BUSINESS

Sunwin Stevia International, Inc., a Nevada corporation, and its subsidiaries are referred to in this report as “we”, “us”, "our”, or “Sunwin”. We changed our name from Sunwin Neutraceuticals International Inc. to Sunwin Stevia International, Inc. on April 23, 2012 to more accurately reflect our business operations.

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines and veterinary products. Substantially all of our operations are located in the People’s Republic of China (the “PRC”). We have built an integrated company with the sourcing and production capabilities designed to meet the needs of our customers.

Our operations are organized into two operating segments related to our Stevioside and Chinese Medicine product lines.

Stevioside Segment

In our Stevioside segment, we produce and sell a variety of purified steviol glycosides with rebaudioside A and stevioside as the principal components, an all natural, low calorie sweetener, and OnlySweet, a stevioside based table top sweetener.

Chinese Medicine Segment

In our Chinese Medicine Segment, we manufacture and sell a variety of traditional Chinese medicine formula extracts which are used in products made for use by both humans and animals.

Qufu Shengwang

In fiscal 2009, Qufu Natural Green acquired a 60% interest in Qufu Shengwang from its shareholder, Shandong Group, for $4,026,851. The purchase price represented 60% of the value of the net tangible assets of Qufu Shengwang as of April 30, 2008. Shandong Group is owned by Laiwang Zhang, our President and Chairman of the Board of Directors.  Qufu Shengwang manufactures and sells stevia -based fertilizers and feed additives.

On September 30, 2011, Qufu Shengwang purchased the 40% equity interest in Qufu Shengwang owned by our Korean partner, Korea Stevia Company, Limited, for $626,125 in cash, and as a result of this repurchase transaction we now own 100% equity interest in all of the net assets of our subsidiary Qufu Shengwang. Therefore, the non-controlling interest of $2,109,028 in our balance sheet as of April 30, 2012 has been eliminated to reflect our 100% interest in Qufu Shengwang. On July 1, 2012, Qufu Shengwang entered the Cooperation Agreement with Hegeng (Beijing) Organic Farm Technology Co, Ltd. (“Hegeng”), a Chinese manufacturer and distributor of bio-fertilizers and pesticides, to jointly develop bio-bacterial fertilizers based on the residues from our stevia extraction. Under the Cooperation Agreement, Hegeng provides strain and formula that we apply to the stevia residues to produce bio-bacterial fertilizers in the current facility of Qufu Shengwang. The bio-bacterial fertilizers will be distributed under Qufu Shengwang’s name.  No additional investment in the facility would be required. During the third quarter of fiscal 2013, we decided to suspend the agreement with Hegeng due to a lack of sales since the reaction to the products was lower than anticipated in fertilizer market. Currently we plan to use these assets to manufacture a variety of traditional Chinese medicine formula extracts. We expect to start production in fiscal 2014.

Qufu Shengren

In fiscal 2009, Qufu Natural Green acquired Qufu Shengren for $3,097,242. The purchase price was equal to the value of the assets of Qufu Shengren as determined by an independent asset appraisal in accordance with asset appraisal principles in the PRC. Prior to being acquired by us, Qufu Shengren was engaged in the production and distribution of bulk drugs and pharmaceuticals.  Subsequent to the acquisition, Qufu Shengren produces and distributes steviosides with a full range of grades from rebaudioside-A 10 to 98.

Sunwin USA

In fiscal 2009, we entered into a distribution agreement with WILD Flavors to assist our 55% owned subsidiary, Sunwin USA, in the marketing and worldwide distribution of our stevioside-based sweetener products and issued WILD Flavors a 45% interest in Sunwin USA.

On August 8, 2012, we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541.  The transaction closed on August 20, 2012. On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors. The $92,541 cash payment was paid by China Direct Investment, Inc. (“CDI”), our corporate management services provider, and reimbursed by us to CDI through the issuance of our common shares as part of the terms of the consulting agreement with CDI dated May 1, 2012. The net tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of generally accepted accounting principles (“U.S. GAAP”) which requires elimination of the difference between the purchase price of the 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets include the product development and supply chain for OnlySweet.

Under the terms of the agreement, WILD Flavors assumed certain pre-closing obligations of Sunwin USA totaling approximately $694,000, including trade accounts receivable, loans, health care and monthly expenses of an employee, potential chargebacks, bank fees and broker commissions incurred prior to the closing date. The agreement also contained customary joint indemnification and general releases.  As a result of this transaction, we began consolidating the operations of Sunwin USA from the date of acquisition (August 20, 2012).

In addition to the Exchange Agreement, on August 8, 2012 we entered into the following additional agreements with WILD Flavors or its affiliate:

-           We entered into an Amendment to Operating Agreement with WILD Flavors pursuant to which we are now the sole manager of Sunwin USA and certain sections of the original agreement dated April 29, 2009 were cancelled as they were no longer relevant following our purchase of the minority interest in Sunwin USA described above;

-           We entered into a Termination of Distribution Agreement with WILD Flavors and Sunwin USA pursuant to which the Distribution Agreement dated February 5, 2009 was terminated; and

-           We entered into a Distributorship Agreement with WILD Procurement Gmbh, a Swiss corporation (“WILD Procurement”) which is an affiliate of WILD Flavors. Under the terms of this agreement, we appointed WILD Procurement as a non-exclusive world-wide distributor for the resale of our stevia products.  There are no minimum purchase quantities under the agreement, and the pricing and terms of each order will be negotiated by the parties at the time each purchase order is placed.  The agreement restricts WILD Procurement from purchasing steviosides or other forms of stevia that are included in our products from sources other than our company under certain circumstances. In addition, at such time as we desire to offer new products, we must first offer WILD Procurement the non-exclusive right to distribute those products and the parties will have 60 days to reach mutually agreeable terms. The agreement contains certain representations by us as to the quality of the products we may sell WILD Procurement and the products’ compliance with applicable laws and good manufacturing practices, as well as customary confidentiality and indemnification provisions.

In the event WILD Procurement should fund research on stevia used in food, beverage or dietary supplement applications, and as a result of this research it develops new intellectual property, such intellectual property shall be the sole property of WILD Procurement. In the event we should jointly fund research, any new intellectual property developed from this effort will be jointly owned and each party will have the right to use the developed intellectual property in stevia-based products.

The agreement is for an initial term of 12 months and will automatically renew for successive 12 month terms unless the agreement has been terminated by either party upon 45 days prior written notice. There are no assurances any purchase orders will be placed under the terms of the Distribution Agreement. The agreement may also be terminated by either party upon a material breach by the other party, or upon the filing of a bankruptcy petition, both subject to certain cure periods. In the event the agreement is terminated, WILD Procurement has the right to continue to distribute our products on a non-exclusive basis for 24 months upon terms and conditions to be negotiated by the parties.

XML

Note 6 - Intangible Assets

9 Months Ended

Jan. 31, 2014

Notes

Note 6 - Intangible Assets

NOTE 6 - INTANGIBLE ASSETS

On August 8, 2012 the Company entered into an Exchange Agreement with WILD Flavors pursuant to which it purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541. In connection with the Exchange Agreement, WILD Flavor granted, transferred and assigned to Sunwin USA all of its rights, title and interest, and the trade name Only Sweet, including any trademarks, trademark registrations and applications, service marks, service mark registrations and applications, copyrights, copyright registrations and applications, trade dress, trade names (whether or not registered or by whatever name or designation), owned, applied for, or registered in the name of, the WILD Flavor (the "Only Sweet Name Rights"). Additionally, we entered into a new Distributorship Agreement with WILD Procurement which is an affiliate of WILD Flavors, as discussed in Note 1. The transaction closed on August 20, 2012. The tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of U.S. GAAP which requires elimination of the difference between the purchase price of the 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets have a useful life of five years and consist of the cost of Only Sweet Name Rights and related technologies as well as the fair value of the Wild Flavors distribution Agreement. For the nine months ended January 31, 2014 and 2013, amortization expense amounted to $243,881 and $135,490, respectively.

            Intangible assets consisted of the following:

(Estimated Life)	January 31, 2014 (Unaudited)	April 30, 2013
Only Sweet name rights and related technologies (5 Years)	$      587,183	$      587,183
Distribution agreement and related distribution channels (5 Years)	1,038,691	1,038,691
Intangible assets, gross	1,625,874	1,625,874
Less: accumulated amortization	(460,665)	(216,784)
Intangible Assets, net	$   1,165,209	$   1,409,090

XML

Note 2- Summary of Significant Accounting Policies: Research and Development (Details) (USD $)	9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Details
Research and Development Expense	$ 24,343	$ 64,541

XML

Note 12- Loan Payable (Details) (USD $)	Mar. 18, 2013
Details
Short-term Bank Loans and Notes Payable	$ 809,822

XML

Note 2- Summary of Significant Accounting Policies: Long-lived Assets (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Long-lived Assets

LONG-LIVED ASSETS

In accordance with ASC Topic 360, we review and evaluate our long-lived assets, including property and equipment, intangible assets, and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates. Based on our evaluation, for the three and nine month ended January 31, 2013, we recorded an impairment loss of $209,194 and $209,194, related to impairment of the carrying amounts certain machinery and equipment deemed unusable as, respectively.

XML

Note 14 - Segment Information: Segment Information Table 2 (Details) (USD $)	3 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Jan. 31, 2013
Details
(Loss) income before income taxes Chinese medicine	$ 98,689	$ 137,625	$ 47,689	$ 149,002
(Loss) income before income taxes Stevioside	(238,493)	(806,192)	(1,705,763)	(1,495,243)
(Loss) income before income taxes Corporate and other	(26,258)	(161,718)	(51,198)	(1,718,715)
Total consolidated (loss) income before income taxes	$ (166,062)	$ (830,285)	$ (1,709,272)	$ (3,064,956)

XML

Note 2- Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)

9 Months Ended

Jan. 31, 2014

Policies

Recent Accounting Pronouncements

RECENT ACCOUNTING PRONOUNCEMENTS

In March 2013, the FASB issued ASU 2013-05 “Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity.” ASU 2013-05 addresses the accounting for the cumulative translation adjustment when a parent either sells part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. For public entities, the ASU is effective prospectively for fiscal years, and interim periods, within those years, beginning after December 15, 2013. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on the Company’s consolidated financial statements.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

XML

Note 16 - Concentrations and Credit Risk

9 Months Ended

Jan. 31, 2014

Notes

Note 16 - Concentrations and Credit Risk

NOTE 16 - CONCENTRATIONS AND CREDIT RISK

(i)    Customer Concentrations

For the nine months ended January 31, 2014 and 2013, customers accounting for 10% or more of the Company’s revenue were as follows:

	Net Revenues
	For the nine months ended January 31, 2014		For the nine months ended January 31, 2013
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Qufu Shengwang Import and Export Trade Co., Ltd (1)	0	41.2%	0	46.0%
Guangdong Tengjun Veterinary Medicine Co., Ltd	0	0	11.6%	0
Total	0%	41.2%	11.6%	46.0%

(1) Qufu Shengwang Import and Export Trade Co., Ltd is a related party, a Chinese entity managed by our Chairman, Mr. Laiwang Zhang.

(ii)    Vendor Concentrations

For the nine months ended January 31, 2014 and 2013, suppliers accounting for 10% or more of the Company’s purchase were as follows:

	Net Purchases
	For the nine months ended January 31, 2014		For the nine months ended January 31, 2013
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd	16.7%	0	38.1%	0
Qufu Longheng Materials Co., Ltd	18.7%	0	34.9%	0
Jiuquan Jiale Biotech Co., Ltd	0	0	0	20.0%
Gansu Fanzhi Biology Technology Co.,Ltd	17.2%	0	0	0
Qingdao Runhao Stevia Technology Co., Ltd	0	0	0	13.0%
Total	52.6%	0%	73.0%	33.0%

(iii)    Credit Risk

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and the PRC. At January 31, 2014, we had $825,525 on deposit in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash held in PRC financial institutions is not insured. We have not experienced any losses in such accounts through January 31, 2014.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.